Methods for treating CFTR-mediated diseases or conditions
By applying a combination of NBD1 stabilizer and TMD1 corrector, ICL4 corrector, or CFTR synergist, the NBD1 domain of ΔF508-CFTR was stabilized, the problem of impaired ΔF508-CFTR function was solved, and significant recovery of CFTR function was achieved.
Patent Information
- Application Number
- CN202580018616.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-06
- Filing Date
- 2025-03-06
- Publication Date
- 2026-11-10
AI Technical Summary
Existing CFTR modulators are unable to restore normal CFTR function for most patients with cystic fibrosis. Impaired folding, transport, and function of ΔF508-CFTR result in sweat chloride levels not reaching the normal range.
Applying a combination of NBD1 stabilizer with TMD1 corrector, ICL4 corrector, or CFTR synergist can improve the maturation and function of ΔF508-CFTR by stabilizing the NBD1 domain.
Improving the maturity of ΔF508-CFTR, making its function approach or reach the level of normal CFTR, and improving the patient's health status.
Smart Images

Figure CN123076598A_ABST
Abstract
Description
Background Technology
[0001] Cystic fibrosis (CF) is caused by mutations in CF transmembrane transport regulators (CFTRs), most commonly ΔF508-CFTR. Approved CFTR modulators enhance their function, providing clinical benefit to eligible patients. Despite progress, current modulators do not provide normal levels of CFTR function for most people with CF, a fact that indicates that average sweat chloride levels are below normal in most eligible patient populations. ΔF508-CFTR results in the loss of phenylalanine F508 within the first nucleotide-binding domain (NBD1) of CFTR. ΔF508 causes NBD1 instability: a key driver of impaired folding, transport, half-life, and function of ΔF508-CFTR. F508 is also involved at the interface of the fourth intracellular loop (ICL4) of the second transmembrane domain (TMD) of NBD1 and CFTR. ΔF508 weakens this interface, exacerbating the molecular pathology of ΔF508-CFTR. Treatments for CFTR-mediated diseases or conditions remain to be found. Summary of the Invention
[0002] This disclosure includes methods for treating CFTR-mediated diseases or conditions, comprising administering an NBD1 stabilizer in combination with one or more additional therapeutic agents, including but not limited to TMD1 correctors and ICL4 correctors. As shown herein and without being bound by any particular theory, complete ΔF508-CFTR correction may require NBD1 stabilization, and without NBD1 stabilization, the correction is significantly reduced. The compounds and methods described herein stabilize NBD1 and can therefore improve patient health. Attached Figure Description
[0003] Figure 1 , Figure 2 , Figure 3 , Figure 4 , Figure 5 and Figure 6 Western blots depicting the effects of compounds 1–7 on ΔF508-CFTR maturation are shown. Western blots of CFSMEo-cells expressing CFTR are also included. Biological replication of cells expressing ΔF508-CFTR and WT-CFTR (as indicated in the treatment) is illustrated. Combinations of compounds 1, 4, 5, 6, or 7 with compounds 2 and / or 3 significantly enhanced ΔF508-CFTR maturation to levels exceeding WT, further demonstrating the synergistic effect between the NBD1 stabilizer and the regulator that resolves domain-domain assembly defects in ΔF508-CFTR.
[0004] Figure 7 , Figure 8 , Figure 9 , Figure 10 and Figure 11 Bar graphs depicting the effects of illustrative compounds 1-7 on the maturation of ΔF508-CFTR are presented. (Compared to TEZ / IVA / ELX in their E...) max The CFTR activity of homozygous ΔF508-CFTR CFHBE cells treated for 48 hours with compounds 1, 4, 5, 6, or 7 alone and / or in combination with compounds 2 and / or 3 was compared to that of cells treated with compounds 3. CFTR-dependent chloride ion transport (minus the FSK peak of the mediator) is expressed as the relative percentage of the average forskolin-stimulated CFTR current (FSK response) from a group of 8 non-CF HBE donors (green bars). Each bar represents the mean ± standard error of 9 CFHBE donors, with 6–8 replicates per donor. When compounds 1, 4, 5, 6, or 7 were combined with ICL4 and / or TMD1 orientation correctors or combinations thereof, CFTR activity reached levels seen in non-CF HBE cells. Detailed Implementation
[0005] definition As used herein, the term "pharmaceutically acceptable salt" means that salts suitable for contact with tissues of humans and lower animals without undue toxicity, irritation, allergic reactions, etc., within the bounds of reasonable medical judgment and in proportion to a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds disclosed herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed by reacting amino groups with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, hydrogen sulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, disglucuronate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucono-heptahydrate, glyceryl phosphate, gluconate, hemisulfate, heptahydrate, hexanoate, hydroiodate, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, dodecyl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, dihydroxynaphthalate, pectate, persulfate, 3-phenylpropionate, phosphate, neopentanoate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc.
[0006] Salts derived from suitable bases include alkali metals, alkaline earth metals, ammonium, and N(C) salts. 1-4 Alkyl)4 salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Where appropriate, other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate ions.
[0007] As used herein, "therapeutic effective amount" means the amount of a substance (e.g., a therapeutic agent, composition, and / or formulation) that elicits a desired biological response. In some embodiments, a therapeutically effective amount of a substance is an amount sufficient to treat, diagnose, prevent, and / or delay the onset of a disease, condition, and / or symptom when administered as part of a dosing regimen to a subject who has or is susceptible to the disease, condition, and / or symptom. As will be understood by those skilled in the art, the effective amount of a substance can vary depending on factors such as the desired biological endpoint, the substance to be delivered, the target cells, or tissues. For example, an effective amount of a compound provided in a formulation for treating a disease, condition, and / or symptom is an amount that reduces, improves, alleviates, inhibits, prevents, delays the onset of one or more symptoms or features of the disease, condition, and / or symptom, reduces their severity, and / or reduces their incidence.
[0008] As used herein, the term "treatment" means to partially or completely reduce, suppress, or delay the onset of a condition or symptom as described herein, or one or more symptoms of such condition or symptom, or to prevent, improve, and / or alleviate such condition or symptom, or one or more symptoms of such condition or symptom. In some embodiments, treatment may be administered after one or more symptoms have developed. In some embodiments, the term "treatment" includes preventing or halting the progression of a disease or symptom. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., based on a history of symptoms and / or based on genetic or other susceptibility factors). Treatment may also continue after symptoms have subsided, for example, to prevent or delay their recurrence. Therefore, in some embodiments, the term "treatment" includes preventing the recurrence or relapse of a disease or symptom.
[0009] As used herein, the term “subject” means animal, preferably mammal, and most preferably human.
[0010] The term "pharmaceutically acceptable excipient" refers to a non-toxic carrier, adjuvant, or mediator that does not impair the pharmacological activity of the compound formulated with it. Pharmaceutically acceptable carriers, adjuvants, or mediators that may be used in compositions of the compounds disclosed herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffering substances such as phosphates, glycine, sorbic acid, potassium sorbate, mixtures of metaglycerides of saturated vegetable fatty acids, water, salts, or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.
[0011] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of ester or other derivative of the compounds disclosed herein, which, upon administration to a recipient, can directly or indirectly provide the compounds disclosed herein or their inhibitory metabolites or residues.
[0012] The compounds disclosed herein In some embodiments, the compound disclosed herein is an NBD1 stabilizer.
[0013] In some implementations, the NBD1 stabilizer is a compound selected from the compounds in Table 1 or their pharmaceutically acceptable salts.
[0014] Table 1
[0015] In some embodiments, the NBD1 stabilizer is a compound of the formula described in International Patent Application No. PCT / US2023 / 073543, the entire contents of which are incorporated herein by reference.
[0016] In some implementations, the NBD1 stabilizer is compound 1, compound 4, compound 5, compound 6, or compound 7: 1 4 5 6 7 Or its pharmaceutically acceptable salt.
[0017] In some embodiments, the compounds disclosed herein are ICL4 correctors. In some embodiments, the ICL4 corrector is elexacaftor (VX-445), vanzacaftor (VX-121), or compound 2. or Or its pharmaceutically acceptable salt.
[0018] In some embodiments, the compounds disclosed herein are TMD1 correctors. In some embodiments, the TMD1 corrector is a compound selected from the group consisting of lumacaftor (VX-809), tezacaftor (VX-661), gallicaftor (ABBV-2222), compound A, and compound 3. Or its pharmaceutically acceptable salt.
[0019] In some embodiments, the compounds disclosed herein are CFTR synergists. In some embodiments, the CFTR synergist is... or Or its pharmaceutically acceptable salt.
[0020] In other embodiments, the compounds disclosed herein are CFTR synergists. In some embodiments, the CFTR synergist is selected from the group consisting of: ivacaftor (VX-770), deutivacaftor (VS-5612), GLPG1837 (AbbVie / Galapagos), GLPG2451 (AbbVie / Galapagos), navocaftor (ABBV-3067), icenticaftor (QBW251 / 6), and dilocaftor (PTI-808).
[0021] In other embodiments, the compounds disclosed herein are CFTR correctors. In some embodiments, the CFTR correctors are selected from the group consisting of: rumacato (VS-809), tizacatato (VX-661), gallicato (ABV-2222), and FDL169 (Flatley Discovery). In other embodiments, the CFTR correctors are selected from the group consisting of: olacaftor (VX-440), bamocaftor (VX-659), elicato (VS-445), venzacatato (VX-121), ABBV-3221 (AbbVie / Galapagos), GLPG / ABBV-2727 (Galapagos / AbbVie), ABBV-3748 (AbbVie), and posevacaftor.
[0022] In other embodiments, the compound disclosed herein is a CFTR amplifying agent. In some embodiments, the CFTR amplifying agent is nesolicaftor.
[0023] In some embodiments, the compounds disclosed herein are compounds of the formulas described in International Patent Application Publications WO2021 / 097057, WO2023 / 034992, WO2024 / 054840, WO2016 / 069757, WO2017 / 009804 and WO2017 / 208115, the contents of which are incorporated herein by reference in their entirety.
[0024] Alternative implementation plan In alternative embodiments, the compounds described herein may also contain one or more isotopic substitutions. For example, hydrogen may be... 2 H (D or deuterium) or 3 H (T or tritium); carbon can be, for example...13 C or 14 C; oxygen can be, for example 18 O; nitrogen can be, for example 15 N, etc. In other embodiments, specific isotopes (e.g., 3 H, 13 C 14 C 18 O or 15 N) can represent at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or at least 99.9% of the total isotopic abundance of the element occupying a specific site in the compound.
[0025] Pharmaceutical Composition In some embodiments, this disclosure provides a composition comprising the compounds disclosed herein and a pharmaceutically acceptable carrier, adjuvant, or mediator. In some embodiments, the amount of the compounds in the contemplated compositions makes it possible to effectively and measurably treat a disease or condition in a biological sample or a subject. In some embodiments, the amount of the compounds in the compositions of this disclosure makes it possible to effectively and measurably treat a disease or condition in a biological sample or a subject. In some embodiments, the contemplated compositions of this disclosure are formulated for administration to a subject who requires such a composition. In some embodiments, the contemplated compositions of this disclosure are formulated for oral administration to a patient.
[0026] In some embodiments, the compositions of this disclosure may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implantable reservoir. In some preferred embodiments, the compositions may be administered orally, intraperitoneally, or intravenously. In some embodiments, the sterile injectable form of a composition comprising one or more of the compounds disclosed herein may be an aqueous or oily suspension. In some embodiments, the suspension may be formulated using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. In some embodiments, the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, such as a solution of 1,3-butanediol. In some embodiments, acceptable media and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. In some embodiments, additional examples include, but are not limited to, sterile, non-volatile oils conventionally used as solvents or suspension media.
[0027] As used in this article, the term "extragastric" includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrasheath, intrahepatic, intralesional, and intracranial injection or infusion techniques.
[0028] Pharmaceutically acceptable compositions comprising one or more of the compounds disclosed herein may be administered orally in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions, or solutions. In some embodiments, the carriers used include lactose and corn starch. Lubricants such as magnesium stearate are also commonly added. In some embodiments, useful diluents include lactose and dried corn starch. In some embodiments, when an aqueous suspension is required for oral administration, the active ingredient is combined with an emulsifier and a suspending agent. In some embodiments, certain sweeteners, flavoring agents, or coloring agents may also be added.
[0029] Pharmaceutically acceptable compositions comprising the compounds disclosed herein may also be applied topically, particularly when the therapeutic target includes areas or organs easily accessible by topical application (including diseases of the eyes, skin, or lower intestine). Suitable topical formulations are readily prepared for each of these areas or organs. In some embodiments, the pharmaceutically acceptable compositions may be formulated in suitable ointments containing an active ingredient suspended or dissolved in one or more carriers. Carriers for the topical application of the compounds disclosed herein include, but are not limited to, mineral oils, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsified waxes, and water. Alternatively, the provided pharmaceutically acceptable compositions may be formulated in suitable lotions or creams containing an active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oils, dehydrated sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecyl alcohol, benzyl alcohol, and water.
[0030] Pharmaceutically acceptable compositions containing the compounds disclosed herein may also be administered via nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the field of pharmaceutical formulation and can be prepared as saline solutions using benzyl alcohol or other suitable preservatives, bioavailability enhancers, fluorocarbons, and / or other conventional solubilizers or dispersants.
[0031] In some embodiments, the amount of the disclosed compounds that can be combined with a carrier material to produce a single dosage form composition will vary depending on the host being treated and the specific administration method. Preferably, the provided compositions should be formulated such that an inhibitor can be administered to a patient receiving these compositions at a dose between 0.01 and 100 mg / kg body weight / day.
[0032] The disclosed compounds can be formulated into pharmaceutical compositions with pharmaceutically acceptable carriers or excipients. In this respect, a pharmaceutical composition is provided comprising the disclosed compounds and pharmaceutically acceptable excipients, diluents, or carriers.
[0033] Formulations of the compounds disclosed herein include those suitable for the routes of administration detailed herein. They are readily available in unit doses and can be formulated into pharmaceutical compositions according to standard pharmaceutical practices. General techniques and formulations applicable to this document can be found in Remington's Pharmaceutical Sciences (16th edition, Osol, A. editor (1980); Mack Publishing Co., Easton, PA). Such methods involve the step of combining the active ingredient with an excipient or carrier constituting one or more auxiliary components. Typically, formulations are prepared by homogenizing and tightly binding the active ingredient with a liquid excipient or carrier, or a finely pulverized solid excipient or carrier, or both, and then shaping the product as needed.
[0034] Acceptable diluents, carriers, excipients, and stabilizers are non-toxic to the recipient at the doses and concentrations used and include buffers such as phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (such as octadecyl dimethyl benzyl ammonium chloride; hexamethyl diammonium chloride; benzalkonium chloride; benzyl chloride; phenol, butyl or benzyl alcohol; alkyl esters of p-hydroxybenzoate such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight peptides (less than about 10 residues); proteins. The active pharmaceutical ingredient may be encapsulated in microcapsules, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, such as sodium ions; metal complexes (such as Zn-protein complexes); and / or nonionic surfactants, such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG). The active pharmaceutical ingredient may also be encapsulated in microcapsules (e.g., hydroxymethyl cellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively) prepared by cohesive techniques or interfacial polymerization, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in crude emulsions. This technology was disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (1980).
[0035] In specific embodiments, the pharmaceutical composition comprising the compounds disclosed herein further comprises a chemotherapeutic agent. In some of these embodiments, the chemotherapeutic agent is an immunotherapeutic agent.
[0036] Methods using the compounds disclosed herein This disclosure includes methods for treating CFTR-mediated diseases or conditions, comprising administering an NBD1 stabilizer in combination with one or more additional therapeutic agents, including but not limited to TMD1 correctors, CFTR enhancers, and ICL4 correctors.
[0037] In some embodiments, this disclosure includes a method of treating a subject with a CFTR-mediated disease or condition, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and an ICL4 corrector. In some embodiments, the NBD1 stabilizer and the ICL4 corrector are administered simultaneously. In some embodiments, the NBD1 stabilizer is administered before the ICL4 corrector. In some embodiments, the NBD1 stabilizer is administered after the ICL4 corrector.
[0038] In some embodiments, this disclosure includes a method of treating a subject with a CFTR-mediated disease or condition, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer, an ICL4 corrector, and a CFTR enhancer. In some embodiments, the NBD1 stabilizer, the TMD1 corrector, and the CFTR enhancer are administered simultaneously. In some embodiments, the NBD1 stabilizer is administered before the ICL4 corrector and / or the CFTR enhancer. In some embodiments, the NBD1 stabilizer is administered after the ICL4 corrector and / or the CFTR enhancer.
[0039] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering a therapeutically effective amount of an NBD1 stabilizer to the subject, wherein the subject has previously received treatment with an ICL4 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering a therapeutically effective amount of an ICL4 corrector to the subject, wherein the subject has previously received treatment with an NBD1 stabilizer.
[0040] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 and compound 2. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 and compound 3. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 and elecato (ELX) or venzacatrol (VX-121).
[0041] In some embodiments, this disclosure includes a method of treating a subject with a CFTR-mediated disease or condition, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and a TMD1 corrector. In some embodiments, the NBD1 stabilizer and the TMD1 corrector are administered simultaneously. In some embodiments, the NBD1 stabilizer is administered before the TMD1 corrector. In some embodiments, the NBD1 stabilizer is administered after the TMD1 corrector.
[0042] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering a therapeutically effective amount of an NBD1 stabilizer to the subject, wherein the subject has previously received treatment with a TMD1 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering a therapeutically effective amount of a TMD1 corrector to the subject, wherein the subject has previously received treatment with an NBD1 stabilizer.
[0043] In some embodiments, this disclosure includes a method of treating a subject with a CFTR-mediated disease or condition, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer, a TMD1 corrector, and a CFTR enhancer. In some embodiments, the NBD1 stabilizer, the TMD1 corrector, and the CFTR enhancer are administered simultaneously. In some embodiments, the NBD1 stabilizer is administered before the TMD1 corrector and / or the CFTR enhancer. In some embodiments, the NBD1 stabilizer is administered after the TMD1 corrector and / or the CFTR enhancer.
[0044] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 with compound A. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 with rumacapto (LUM), tezacotto (TEZ), or gallicato (ABV-2222).
[0045] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and an ICL4 corrector and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 and compound 2 and compound 3. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 and elecato or venzaccato and compound 3. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 1, compound 4, compound 5, compound 6, or compound 7 in combination with compound 2 and compound A or tezacator (TEZ) or rumacator (LUM) or gallicato (ABBV-2222). In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 1, compound 4, compound 5, compound 6, or compound 7 in combination with elecato (ELX) or venzacator (VX-121) and compound A or tezacator (TEZ) or rumacator (VX-809) or gallicato (ABBV-2222).
[0046] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and an ICL4 corrector and a CFTR enhancer. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 with elecato (ELX), venzaccato (VX-121), compound 2, or compound 3, and a therapeutically effective amount of ivaccato, deutericatato, navoccato, or esenccato.
[0047] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and a TMD1 corrector and a CFTR enhancer. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 with compound A, rumacapto (LUM), tezacotto (TEZ), or gallicato, and a therapeutically effective amount of ivacapto, deutericcapto, navocapto, or esencapto. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and an ICL4 corrector, a TMD1 corrector, and a CFTR enhancer. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 1, compound 4, compound 5, compound 6, or compound 7 in combination with elecato (ELX), tezacto (TEZ), or compound A, and ivacato (IVA) or venzacato (VX-121), tezacto (TEZ), and deutericto. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 1, compound 4, compound 5, compound 6, or compound 7 in combination with compound 2, tezacto (TEZ), and ivacato (IVA).
[0048] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and Trikafta. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1, compound 4, compound 5, compound 6, or compound 7 and Trikafta.
[0049] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and a TMD1 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and compound 3.
[0050] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and an ICL4 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and compound 2.
[0051] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and compound 3. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and compound A.
[0052] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 5 in combination with an ICL4 corrector and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 5 in combination with compound 2 and glycartosol. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 5 in combination with compound 2 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 5 in combination with compound 2 and compound 3.
[0053] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 4 and an ICL4 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 4 and compound 2.
[0054] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 4 and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 4 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 4 and compound 3. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 4 and compound A.
[0055] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 4 in combination with an ICL4 corrector and a TMD1 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 5 in combination with compound 4 and glycartosol. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 4 in combination with compound 2 and ABBV-2222. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 4 in combination with compound 2 and compound 3.
[0056] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 6 and an ICL4 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 6 and compound 2.
[0057] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 6 and a TMD1 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 6 and ABBV-2222. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 6 and compound 3. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 6 and compound A.
[0058] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 6 in combination with an ICL4 corrector and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 6 in combination with compound 2 and glycartosol. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 6 in combination with compound 2 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 6 in combination with compound 2 and compound 3.
[0059] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 7 and an ICL4 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 7 and compound 2.
[0060] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 7 and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 7 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 7 and compound 3. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 7 and compound A.
[0061] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 7 in combination with an ICL4 corrector and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 7 in combination with compound 2 and glycartosol. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 7 in combination with compound 2 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of compound 7 in combination with compounds 2 and 3.
[0062] In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and an ICL4 corrector. In some embodiments, this disclosure includes a method of treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 5 and compound 2.
[0063] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and compound 3. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and compound A.
[0064] In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and an ICL4 corrector and a TMD1 corrector. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and compound 2 and galatic valerate. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and compound 2 and ABBV-2222. In some embodiments, this disclosure includes a method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of compound 1 and compounds 2 and 3.
[0065] example Analysis program High-performance liquid chromatography-mass spectrometry (LC-MS) was performed using one of the following methods to determine the retention time (RT) and associated mass ions of the compound.
[0066] LC-MS Method 1: Mobile phase: A: Water (0.01% TFA). B: ACN (0.01% TFA). Gradient: 5% - 95% B over 1.5 min. Flow rate: 2.0 mL / min. Column: Sunfire C18, 4.6 × 50 mm, 3.5 µm. Column oven temperature: 50 °C. Mass range: 110-1000. UV (214 nm, 254 nm).
[0067] LC-MS Method 2: Column: Xbridge C18(2) (4.6 × 50 mm, 3.5 µm). Mobile phase: H2O (10 mmol NH4HCO3) (A) / ACN (B). Elution program: gradient of 10% to 95% B over 1.5 min, 1.8 mL / min. Temperature: 50 °C. Detection: UV (214 nm, 254 nm) and MS (ESI, positive ion mode, 103 to 800 amu).
[0068] LC-MS Method 3: Mobile phase: A: Water (0.01% trifluoroacetic acid), B: Acetonitrile (0.01% trifluoroacetic acid); Gradient: 5% B increased to 95% B over 1.3 min, 95% B sustained for 1.7 min, and returned to 5% B over 0.01 min; Flow rate: 2 ml / min; Column: Sunfire, 50 x 4.6 mm, 3.5 μm; Column temperature: 50 °C; Detection: UV (214.4 nm) and MS (ESI, positive ion mode, 110 to 1000 amu). LC-MS Method 4: Mobile phase: A: Water (0.01% trifluoroacetic acid), B: Acetonitrile (0.01% trifluoroacetic acid); Gradient: 5% B increased to 95% B over 1.5 min, 95% B sustained for 1.5 min, and returned to 5% B over 0.01 min. Flow rate: 1.8 mL / min; Column: Sunfire C18, 4.6*50 mm, 3.5 µm; Column oven temperature: 50 °C.
[0069] LC-MS Method 5: Mobile phase: Water (10 mM ammonium bicarbonate) (A) / acetonitrile (B); Gradient: B = 5% B increased to 95% B in 1.4 min, 95% B sustained for 1.6 min, and returned to 5% B in 0.01 min; Flow rate: 1.8 mL / min; Column: Xbridge-C18, 50 x 4.6 mm, 3.5 µm; Column temperature: 50 °C.
[0070] LC-MS Method 6: Mobile phase: A: water (0.1% formic acid) B: acetonitrile (0.1% formic acid), gradient: 10% B for 0.2 min, increasing to 90% B in 1.3 min, 90% B for 1.5 min; flow rate: 2 mL / min; column: Sunfire C18, 4.6 x 50 mm, 3.5 μm; column oven temperature: 50 °C; detection: UV (214.4 nm) and MS (ESI, positive ion mode, 110 to 1000 amu).
[0071] LC-MS Method 7: Column: SUNFIRE C18 (4.6 x 50 mm, 3.5 µm); Mobile phase: A: Water (0.01% trifluoroacetic acid) (A) / Acetonitrile (0.01% trifluoroacetic acid) (B); Elution program: Gradient of 5% to 95% B over 3 min, 95% for 2 min, 2.0 mL / min. Column oven temperature: 50 °C; Detection: UV (214.4 nm) and MS (ESI, positive ion mode, 110 to 1000 amu). LC-MS Method 8: Column: SunFire C18 (4.6 x 50 mm, 3.5 µm); Mobile phase: A: Water (0.01% trifluoroacetic acid) B: Acetonitrile (0.01% trifluoroacetic acid); Gradient: 10% to 95% B over 1.4 min, 95% B for 1.6 min; Flow rate: 2 mL / min; Temperature: 50 °C; Detection: UV (214, 4 nm) and MS (ESI, positive ion mode, 110 to 1000 amu).
[0072] LC-MS Method 9: Mobile phase: A: Water (0.01% trifluoroacetic acid) B: Acetonitrile (0.01% trifluoroacetic acid) Gradient: 5% B to 95% B over 1.3 min, 95% B sustained for 1.78 min Flow rate: 1.6 mL / min; Column: Agilent Poroshell, 30*3.0 mm, 2.7 µm; Column temperature: 50 °C; Detection: UV (214, 4 nm) and MS (ESI, positive ion mode, 110 to 1000 amu).
[0073] LC-MS Method 10: Mobile phase: A: Water (0.01% trifluoroacetic acid) B: Acetonitrile (0.01% trifluoroacetic acid); Gradient: 5% to 95% B over 1.5 min, 95% B sustained for 1.7 min; Flow rate: 2.0 mL / min; Column: Sunfire C18, 4.6*50 mm, 3.5 µm; Column temperature: 50 °C; Detection: UV (214, 4 nm) and MS (ESI, positive ion mode, 110 to 1000 amu).
[0074] LC-MS Method 11: Mobile phase: A: Water (0.01% trifluoroacetic acid) B: Acetonitrile (0.01% trifluoroacetic acid); Gradient: 5% to 95% B in 1.05 min, 95% B to 2.90 min, then back to 5% B in 0.05 min; Flow rate: 1.6 mL / min; Column: Proshell 120 EC-C18, 30*3 mm, 2.7 µm; Column oven temperature: 50 °C; Detection: UV214, MASS 103-1000 amu.
[0075] LC-MS Method 12: Mobile phase: A: Water (0.01% trifluoroacetic acid) B: Acetonitrile (0.01% trifluoroacetic acid); Gradient: 5% B increased to 95% B over 9 minutes, 95% B sustained for 6 minutes; Flow rate: 1 mL / min; Column: Sunfire C18 150 * 4.6 mm, 3.5 µm; Column temperature: 45 °C; Detection: UV (214 nm, 4 nm) and MS (ESI, positive ion mode, 110–1300 amu).
[0076] 1 ¹H NMR spectra were collected at 400 MHz on a Gemini 400 or Varian Mercury 400 spectrometer (unless otherwise specified) using an ASW 5 mm probe, and were typically recorded at ambient temperature in deuterated solvents such as D₂O, DMSO-D₆, CH₃OH-d₄, or CDCl₃, unless otherwise specified. Chemical shift values (δ) are expressed in parts per million (ppm) relative to tetramethylsilane (TMS) used as an internal standard.
[0077] abbreviation: ACN: Acetonitrile Boc: tert-butoxycarbonyl DEA: Diethylamine DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene DCE: 1,2-Dichloroethane DCM: Dichloromethane DIAD: Diisopropyl azodicarbonate DMAP: 4-Dimethylaminopyridine DMSO: Dimethyl sulfoxide dppf: 1,1'-bis(diphenylphosphine)ferrocene EA: Ethyl acetate ee: Enantiomer excess ESI: Electrospray Ionization HPLC: High Performance Liquid Chromatography LC-MS: Liquid Chromatography-Mass Spectrometry MsCl: Methanesulfonyl chloride Pd / C: Palladium / Carbon rt: room temperature PE: Petroleum ether SFC: Supercritical Fluid Chromatography TBS: tert-butyldimethylsilyl TIPS: Triisopropylsilyl THF: Tetrahydrofuran THP: Tetrahydropyran Ts: Toluenesulfonyl group General disclaimers regarding stereochemistry It should be understood that the absolute stereochemistry of all intermediates and examples described herein has not been determined. Assigning the chiral center to R or S is entirely arbitrary and merely... To distinguishDifferent fractions (P1 and P2) eluted from rapid column chromatography, preparative HPLC, chiral HPLC, or SFC. P1 or P2 does not have an S or R identifier. connect .
[0078] Both ChemDraw and Mol2Nam from OpenEye Scientific software have been used to generate compound names. In case of discrepancies, the structure should prevail.
[0079] Example 1. Diastereomers of 2-[3-(22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-9,24-dioxa-12λ6-thia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl)phenyl]acetic acid (compound 1) 2-Fluoro-5-((6-fluoro-4-bromo-1H-indol-5-yl)oxy)benzothioamide 2-fluoro-5-((6-fluoro-4-bromo-1H-indol-5-yl)oxy)benzyl nitrile (30 mmol) and sodium hydrosulfide (10.1 g, 180 mmol) were reacted in... N,N A solution of magnesium chloride (8.58 g, 90.1 mmol) in water (20 mL) was added to a stirred solution of dimethylformamide (100 mL). The mixture was stirred at room temperature for 1 hour, then quenched with water (300 mL). The mixture was extracted with ethyl acetate (2 × 200 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated to give the title compound.
[0080] 5-((4-bromo-6-fluoro-1H-indol-5-yl)oxy)-2-fluorobenzoimide thiocarboxylic acid (benzimidothioate) methyl hydroiodide Iodomethane (3.30 mL, 7.52 g, 53.0 mmol) was added to a stirred solution of 2-fluoro-5-((6-fluoro-4-bromo-1H-indol-5-yl)oxy)benzothioamide (10.6 mmol) in acetone (40 mL). The mixture was heated to 40 °C and maintained at that temperature overnight. The reaction mixture was then cooled to room temperature and concentrated. The crude title compound was obtained, which was used directly without purification.
[0081] 2-(3-iodophenyl)propionate tert-butyl ester Over 30 minutes, a 2.0 M solution of lithium diisopropylaminoacetate in tetrahydrofuran (217 mL, 434 mmol) was added dropwise to a stirred and cooled (-78 °C) solution of tert-butyl 2-(3-iodophenyl)acetate (115 g, 361 mmol) in tetrahydrofuran (800 mL). The mixture was maintained at -78 °C for two hours, followed by dropwise addition of methyl iodoform (23.6 mL, 53.8 g, 379 mmol) over 10 minutes. The reaction mixture was warmed to room temperature and stirred for another two hours. Subsequently, the reaction mixture was quenched by the slow addition of water (800 mL) and then concentrated to remove the organic solvent. The remaining water / oil mixture was extracted with ethyl acetate (1 x 500 mL), and the organic layer was washed with brine (2 x 500 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, 0-5% ethyl acetate / petroleum ether) to give the title compound (97.9 g, 82%) as a colorless oil. MS (ESI): 355 m / z [M+Na] + .
[0082] 7-Hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester Over 20 minutes, a 2.0 M solution of lithium diisopropylamino in tetrahydrofuran (177 mL, 354 mmol) was added dropwise to a solution of tert-butyl 2-(3-iodophenyl)propionate (97.9 g, 295 mmol) in tetrahydrofuran (800 mL) under stirring and cooling (-78 °C). The mixture was maintained at -78 °C for two hours, followed by dropwise addition of tert-butyl((5-iodo-2,2-dimethylpentyl)oxy)dimethylsilane (110 g, 309 mmol) over 20 minutes. The reaction mixture was warmed to room temperature and stirred overnight. Subsequently, the reaction mixture was quenched by the slow addition of water (800 mL) and then concentrated to remove the organic solvent. The remaining water / oil mixture was extracted with ethyl acetate (1 x 500 mL), and the organic layer was washed with brine (2 x 500 mL), dried over anhydrous sodium sulfate, and concentrated. The residue was subjected to automated rapid chromatography (330... Purification was performed using a 330 g silica gel column (0-5% ethyl acetate / petroleum ether) to give the title compound (160 g, 97%) as a light amber oil. A fraction of this material (100 g, 178 mmol) was dissolved in tetrahydrofuran (400 mL), stirred at room temperature, and treated with tetrabutylammonium fluoride in a 1.0 M solution of tetrahydrofuran (357 mL, 357 mmol). The mixture was stirred overnight at room temperature and then partitioned between ethyl acetate (500 mL) and water (800 mL). The organic layer was washed with a further fraction of water (2 x 800 mL), dried over magnesium sulfate, and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, 0-30% ethyl acetate / petroleum ether) to give the title compound (65.1 g, 79% total, two steps) as a colorless oil. MS (ESI): 469 m / z [M+Na] + .
[0083] 7-(acetylthio)-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester Over 10 minutes, diisopropyl azodicarbonate (86.0 mL, 88.3 g, 437 mmol) was added dropwise to a solution of triphenylphosphine (115 g, 438 mmol) in tetrahydrofuran (800 mL) under stirring and cooling (0 °C). The reaction mixture was maintained at 0 °C, and the appearance of a precipitate was monitored. When a white solid was observed, a pre-prepared solution of tert-butyl 7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptahydrate (65.0 g, 146 mmol) and thioacetic acid (31.2 mL, 33.2 g, 437 mmol) in tetrahydrofuran (200 mL) was added dropwise. After the addition, the reaction mixture was stirred at 0 °C for one hour, then heated to room temperature and stirred for another hour. The reaction mixture was then concentrated, and the crude residue was subjected to automated rapid chromatography (330 g silica gel column, 0-10% ethyl acetate / petroleum ether). The title compound (51.0 g, 69%) was obtained as a viscous, light amber oil. MS (ESI): 527 m / z [M+Na] + .
[0084] 7-((2-hydroxyethyl)thio)-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester tert-butyl heptanoate (51.0 g, 101 mmol) was added to a stirred solution of 7-(acetylthio)-2-(3-iodophenyl)-2,6,6-trimethylheptahydrate (300 mL) with 2-bromoethanol (9.32 mL, 16.4 g, 131 mmol), followed by sodium ethoxide (10.3 g, 151 mmol). The reaction mixture was stirred for one hour, and then partitioned between ethyl acetate (500 mL) and water (800 mL). The organic layer was washed with a separate portion of water (2 x 800 mL), dried over magnesium sulfate, and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, 0-20% ethyl acetate / petroleum ether) to give the title compound (47.2 g, 92%) as a pale amber gel. MS (ESI): 529 m / z [M+Na] + .
[0085] 7-((2-hydroxyethyl)sulfonyl)-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester A solution of ammonium molybdate tetrahydrate (34.0 g, 27.5 mmol) dissolved in 30% aqueous hydrogen peroxide solution (150 mL) was added to a stirred solution of 7-((2-hydroxyethyl)thio)-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester (34.0 g, 67.1 mmol) in methanol (1.2 L). After two hours at room temperature, the reaction mixture was partitioned between ethyl acetate (1.5 L) and water (2 L). The organic layer was washed with a second portion of water (1 x 2 L), dried over sodium sulfate, and concentrated. The crude title compound (32.8 g, 91%) was given as a light amber gel. MS (ESI): 561 m / z [M+Na] + .
[0086] 7-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-2-(3-iodophenyl)-2,6,6-trisyl) tert-butyl methyl heptanoate To a stirred solution of 7-((2-hydroxyethyl)sulfonyl)-2-(3-iodophenyl)-2,6,6-trimethylheptahydrate tert-butyl ester (32.0 g, 59.4 mmol) in dichloromethane (500 mL), imidazole (8.09 g, 119 mmol) and tert-butyldimethylsilyl chloride (10.7 g, 71.0 mmol) were added. After two hours at room temperature, the reaction mixture was partitioned between dichloromethane (400 mL) and water (500 mL). The organic layer was washed with a second portion of water (1 x 500 mL), dried over magnesium sulfate, and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, 0-20% ethyl acetate / petroleum ether) to give the title compound (34.0 g, 88%) as a pale amber gel. 1 H NMR (400 MHz, CDCl3) δ 7.64(t, J = 1.9 Hz, 1H), 7.55 (dt, J = 7.8, 1.9 Hz, 1H), 7.28-7.26 (m, 1H), 7.04 (t, J = 8.0 Hz, 1H), 4.04 (t, J= 5.2 Hz, 2H), 3.09-3.05 (m, 4H), 1.99-1.92 (m, 1H), 1.83-1.75 (m, 1H), 1.54-1.50 (m, 2H), 1.45 (s, 3H), 1.39 (s, 9H), 1.28-1.23(m, 2H), 1.17 (s, 3H), 1.15 (s, 3H), 0.90 (s, 9H), 0.09 (s, 6H) ppm.
[0087] 7-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-2-(3-((R)-3-methoxy-2- tert-butyl methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptanoate The reaction was carried out in a glove box under positive pressure using dry nitrogen. Zinc powder (12.0 g, 184 mmol) was... N,N Iodine (0.778 g, 3.07 mmol) was added to a stirred suspension of dimethylformamide (200 mL). After 40 minutes at room temperature, the mixture was... S Treatment with methyl 3-iodo-2-methylpropionate (14.0 g, 61.4 mmol). Allow the organic zinc iodide reagent to recombine for 40 minutes, then add the following in sequence: SPhos (2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (1.26 g, 3.07 mmol), tris(dibenzylacetone)dipalladium(O) (1.40 g, 1.53 mmol) and 7-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester (20.0 g, 30.6 mmol). Stir the reaction mixture overnight at room temperature. Afterward, remove the mixture from the glove box and filter it through a diatomaceous earth stopper. Wash the filtrate with ethyl acetate (approximately 200 mL) and partition the combined filtrates between water (600 mL) and ethyl acetate (200 mL). Combine the organic layer with the additional extract (ethyl acetate, 2 x 200 mL) and rinse with brine (2 x 200 mL). The solution was washed (mL) and dried over sodium sulfate. The solution was then concentrated to give a residue, which was subjected to automated rapid chromatography (330 g silica gel column, 0-20% ethyl acetate / petroleum ether). The title compound (16.0 g, 83% yield) was given as a light amber gel. MS (ESI): 649 m / z [M+Na] + .
[0088] 7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2,6, tert-butyl 6-trimethylheptanoate To 7-((2-(( Uncle Butyl dimethylsilyl)oxy)ethyl)sulfonyl)-2-(3-(( R )-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptanoic acid Uncle Butyl ester (16.0 g, 25.5 mmol) was added to a stirred solution of 1,4-dioxane (100 mL) with 4 M hydrogen chloride in 1,4-dioxane (63.8 mL, 255 mmol). After three hours at room temperature, the reaction mixture was concentrated. The residue was purified by automated rapid chromatography (120 g silica gel column, 0-40% ethyl acetate / petroleum ether) to give the title compound (12.0 g, 92%) as a viscous solid. MS (ESI): 535 m / z [M+Na] + .
[0089] 7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2,6, 6-Trimethylheptanoic acid 7-((2-hydroxyethyl)sulfonyl)-2-(3-( R 3-Methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptahydrate tert-butyl ester (12.0 g, 23.4 mmol) was added to a stirred solution of dichloromethane (100 mL) with trifluoroacetic acid (17.4 mL, 25.9 g, 227 mmol). The mixture was concentrated after two hours at room temperature. The residue was subjected to automated rapid chromatography (120 g silica gel column, 0-60% ethyl acetate / petroleum ether, 40 min). The title compound (9.11 g, 85%) was given as a pale amber solid. MS (ESI): 479 m / z [M+Na] + .
[0090] 2-(7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2, 6,6-Trimethylheptanoyl)-1-methylhydrazine-1-carboxylic acid tert-butyl ester 7-((2-hydroxyethyl)sulfonyl)-2-(3-( R 3-Methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptanoic acid (9.10 g, 19.9 mmol) and tert-butyl 1-methylhydrazine formate (3.25 mL, 3.20 g, 21.9 mmol) were added to a stirred solution of acetonitrile (100 mL) with 1-methylimidazole (5.73 g, 69.9 mmol), followed by the addition of chloro- N , N , N ′,N ′-Tetramethylformamidinium hexafluorophosphate (5.59 g, 19.9 mmol). After one hour at room temperature, the reaction mixture was partitioned between ethyl acetate (200 mL) and water (300 mL). The organic layer was washed with another portion of water (1 x 300 mL), dried over magnesium sulfate, and concentrated. The residue was purified by automated rapid chromatography (120 g silica gel column, 0-60% ethyl acetate / petroleum ether) to give the title compound (10.0 g, 86% yield) as a pale amber gel. MS (ESI): 607 m / z [M+Na] + .
[0091] (2R)-3-(3-(7-((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazyl)-1-oxoheptane- Methyl 2-yl)phenyl)-2-methylpropionate 2-(7-((2-hydroxyethyl)sulfonyl)-2-(3-(( R 3-Methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptanoyl)-1-methylhydrazine-1-carboxylic acid tert-butyl ester (10.0 g, 17.1 mmol) was added to a stirred solution of dichloromethane (100 mL) with trifluoroacetic acid (12.4 mL, 18.5 mL, 162 mmol). After two hours at room temperature, the reaction mixture was concentrated. The residue was partitioned between ethyl acetate (200 mL) and an aqueous solution of sodium bicarbonate (200 mL). The organic layer was combined with a separate extract (ethyl acetate, 2 x 100 mL), dried over sodium sulfate, and concentrated. The crude material was purified by automated rapid chromatography (120 g silica gel column, 0-60% ethyl acetate / petroleum ether) to give the title compound (7.83 g, 94% yield) as a pale amber solid. MS (ESI): 485 m / z [M+H] + .
[0092] (2R)-3-(3-(2-(5-(5-((4-bromo-6-fluoro-1H-indol-5-yl)oxy)-2-fluorophenyl)-1-methyl- 1H-1,2,4-triazol-3-yl)-7-((2-hydroxyethyl)sulfonyl)-6,6-dimethylhept-2-yl)phenyl)-2-methylpropionate methyl ester Step A: To (2 RMethyl 3-(3-(7-(((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazyl)-1-oxohept-2-yl)phenyl)-2-methylpropionate (7.81 g, 16.1 mmol) was added to a stirred solution of pyridine (100 mL) with methyl 5-((4-bromo-6-fluoro-1H-indol-5-yl)oxy)-2-fluorobenzoimide thiocarbamate hydroiodate (9.30 g, 17.7 mmol). The mixture was heated at 80 °C for four hours, then cooled to room temperature and partitioned between 1.0 M hydrochloric acid (200 mL) and ethyl acetate (300 mL). The organic layer was washed with brine (2 x 300 mL), dried over sodium sulfate, and concentrated to give a solid, which was subjected to automated rapid chromatography (80 g silica gel column, 0-60% ethyl acetate / petroleum ether). The title compound (7.92 g, 60%) was obtained as a brownish-brown solid. MS (ESI): 815, 817 m / z [M+H] + .
[0093] (2R)-3-(3-(2-(5-(5-((4-bromo-6-fluoro-1H-indol-5-yl)oxy)-2-fluorophenyl)-1-methyl- methyl 1H-1,2,4-triazol-3-yl)-6,6-dimethyl-7-(vinylsulfonyl)hept-2-yl)phenyl)-2-methylpropionate Step B: Triethylamine (4.05 mL, 2.94 g, 29.1 mmol) was added to a stirred solution of dichloromethane (100 mL), followed by the addition of methanesulfonyl chloride (0.825 µL, 1.22 g, 10.7 mmol). After two hours at room temperature, the mixture was partitioned between another 150 mL of dichloromethane and 200 mL of brine. The organic layer was washed with a second portion of brine (1 x 200 mL), dried over sodium sulfate, and concentrated. The residue was purified by automated rapid chromatography (120 g silica gel column, 0-50% ethyl acetate / petroleum ether) to give the title compound (6.50 g, 84%) as a brown solid. MS (ESI): 797, 799 m / z [M+H] + .
[0094] (2R)-3-[3-[22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-24-oxa-12λ6-thio Hetero-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,13,15, Methyl 17,20,22,25,27-decen-6-yl]phenyl]-2-methylpropionate Step C: The reaction was carried out in a glove box under positive pressure of dry nitrogen. Bis(tri-tert-butylphosphine)palladium(O) (0.833 g, 1.63 mmol) and triethylamine (11.4 mL, 8.28 g, 81.8 mmol) were added to a stirred solution of toluene (1 L) of the product from Step B (6.50 g, 8.15 mmol). The mixture was heated at 100 °C for two hours, then cooled to room temperature and concentrated. The residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was washed with a second portion of water (1 x 200 mL), dried over sodium sulfate, and concentrated to give a brown solid. The crude material was subjected to automated rapid chromatography (80 g silica gel column, 0-50% ethyl acetate / petroleum ether). The title compound (2.81 g, 48%) was given as a light amber solid. MS (ESI): 717 m / z [M+H] + .
[0095] (2R)-3-[3-(22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-24-oxa-12λ6-thio] Hetero-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17, Methyl 20,22,25,27-nonen-6-yl)phenyl]-2-methylpropionate Step D: The stirred suspension of the product from Step C (2.80 g, 3.91 mmol) and 10% palladium / carbon (0.800 g in a 50% aqueous dispersion) in ethanol (50 mL) was circulated three times between vacuum and nitrogen atmosphere. After the last evacuation, the reaction vessel was backfilled with hydrogen (via a gasket). The mixture was heated at 50 °C for two hours, then cooled to room temperature and exposed to air. The catalyst was removed by suction filtration through a diatomaceous earth pad, which was subsequently washed with ethanol (2 x 30 mL). The combined filtrates were concentrated to give the crude title compound (used directly as a white solid) (2.62 g, 93%). MS (ESI): 719 m / z [M+H] + .
[0096] (2R)-3-[3-(22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-24-oxa-12λ6-thio] Hetero-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17, Diastereomers 1 and 2 of methyl 20,22,25,27-nonen-6-yl)phenyl]-2-methylpropionate Step E: The product of Step D was separated into its two constituent diastereomers using a Thar SFC-200 instrument and the following separation conditions: Column: 20 x 250 mm x 10 μm CHIRALPAK AD; Sample solution: 2.50 g dissolved in methanol (140 mL); Injection volume: 1.5 mL; Eluent: 85:15 CO2 / methanol with 0.2% ammonia / methanol additive; Flow rate: 130 mL / min; Column temperature: 35 °C; Back pressure: 100 bar; Detection wavelength: 214 nm. The first eluted isomer was designated diastereomer 1 (1.16 g, 46%), and the second eluted isomer was designated diastereomer 2 (1.07 g, 43%). Both were obtained as white solids.
[0097] diastereomer 1: 1 H NMR (400 MHz, CD3OD) δ 7.40-7.30 (m, 3H), 7.26-7.14(m, 3H), 7.07-7.02 (m, 1H), 7.00-6.93 (m, 2H), 6.63 (dd, J = 3.2, 0.7 Hz, 1H), 3.87 (d, J = 2.3 Hz, 3H), 3.56 (s, 3H), 3.43-3.35 (m, 2H), 3.31-3.17 (m, 2H), 2.97 (d, J = 13.5 Hz, 1H), 2.89-2.78 (m, 2H), 2.71-2.60 (m, 2H), 2.20-2.09 (m,1H), 1.88-1.79 (m, 1H), 1.69 (s, 3H), 1.67-1.52 (m, 1H), 1.39-1.17 (m, 3H),1.11-1.01 (m, 9H) ppm.
[0098] diastereomer 2: 1 H NMR (400 MHz, CD3OD) δ 7.40-7.31 (m, 3H), 7.26-7.14(m, 3H), 7.05-7.00 (m, 1H), 7.00-6.94 (m, 2H), 6.63 (dd, J = 3.2, 0.7 Hz, 1H), 3.88 (d, J= 2.3 Hz, 3H), 3.55 (s, 3H), 3.43-3.35 (m, 2H), 3.32-3.16 (m, 2H), 2.95 (d, J = 13.6 Hz, 1H), 2.91-2.83 (m, 1H), 2.80 (d, J = 13.6 Hz, 1H), 2.71-2.60 (m, 2H), 2.21-2.10 (m, 1H), 1.87-1.77 (m, 1H), 1.68 (s, 3H), 1.67-1.55(m, 1H), 1.39-1.28 (m, 1H), 1.25-1.16 (m, 1H), 1.13-0.98 (m, 10H) ppm.
[0099] Compound 1 ( (2R)-3-[3-(22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-24-oxa-] 12λ6-thia-3,4,19,30-tetraazapentacyclic[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30), The diastereomeric form of 4,15,17,20,22,25,27-nonen-6-yl)phenyl]-2-methylpropionic acid 1 Step F: Add 1.0 M lithium hydroxide aqueous solution (4.6 mL, 4.6 mmol) to a stirred solution of diastereomer 1 (1.10 g, 1.53 mmol) in a 3:1 tetrahydrofuran / methanol (20 mL) solution. After four hours at room temperature, the reactants were acidified by adding 1.0 M hydrochloric acid (10 mL). The resulting suspension was extracted with ethyl acetate (1 x 50 mL), and the organic layer was washed with brine (2 x 20 mL), dried over sodium sulfate, and concentrated. The crude product was purified by automated rapid chromatography (12 g silica gel column, 0-70% ethyl acetate / petroleum ether) to 1 (0.902 g, 84%) as a white solid. To confirm the propionic acid chiral center of this molecule incorporation into the molecule (with ( S Following the Negishi coupling reaction of 3-methoxy-2-methyl-3-oxopropyl zinc iodide, no epimerization occurred. The compound was examined by chiral HPLC using a method capable of separating it from its enantiomer and the epimer with its propionic acid chiral center reversed. The chiral purity was determined to be ≥97.4%, with 1.6% impurities from the α-carbonyl epimer and 1% or less impurities from the enantiomer. Given the (…) used to prepare the zinc iodide reagent (steps A and H) RThe specified purity (99%) of the starting material for methyl 3-hydroxy-2-methylpropionate indicated minimal loss of chiral purity due to subsequent synthetic steps. Chiral analysis was performed using an Agilent 1200 HPLC system under the following separation conditions: Column: 4.6 x 250 mm x 5 µm Chiralpak AD-H; Sample solution: 1.0 mg / mL; Injection volume: 10 µL; Eluent: 85:15 heptane / isopropanol containing 0.1% trifluoroacetic acid; Flow rate: 1.0 mL / min; Column temperature: 23 °C; Detection wavelength: 254 nm. Observed retention times: 1, 16.75 min; epimer, 12.81 min; enantiomer, 20.56 min.
[0100] Compound 1: 1 H NMR (400 MHz, CD3OD) δ 7.39-7.30 (m, 3H), 7.25-7.13 (m,3H), 7.07-6.97 (m, 3H), 6.63 (d, J = 3.2 Hz, 1H), 3.87 (d, J = 2.1 Hz, 3H), 3.44-3.37 (m, 2H), 3.36-3.27 (m, 1H), 3.26-3.16 (m, 1H), 2.99-2.88 (m, 2H), 2.81(d, J = 13.6 Hz, 1H), 2.68-2.55 (m, 2H), 2.16 (dt, J = 12.8, 3.6 Hz, 1H), 1.84(dt, J = 12.8, 4.4 Hz, 1H), 1.75-1.51 (m, 4H), 1.40-1.28 (m, 1H), 1.28-1.14 (m,1H), 1.14-0.95 (m, 10H) ppm. MS (ESI): 705 m / z [M+H] + LC R t Purity (LC-MS method 01): 1.44 min, >99.9% / 96.8% (210 / 254 nm).
[0101] Compound 1A ( (2R)-3-[3-(22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-24-oxa-] 12λ6-thia-3,4,19,30-tetraazapentacyclic[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30), The diastereomeric form of 4,15,17,20,22,25,27-nonen-6-yl)phenyl]-2-methylpropionic acid 2 Step G: Hydrolyze the diastereomer 2 product (1.00 g, 1.39 mmol) from step E using the same procedure as described in step F to give the title compound (0.846 g, 86%) as a white solid.
[0102] Compound 1A: 1 H NMR (400 MHz, CD3OD) δ 7.40-7.29 (m, 3H), 7.27-7.12 (m,3H), 7.09-6.94 (m, 3H), 6.63 (d, J = 3.1 Hz, 1H), 3.87 (d, J = 2.0 Hz, 3H), 3.47-3.35 (m, 2H), 3.33-3.16 (m, 2H), 3.02-2.88 (m, 2H), 2.82 (d, J = 13.6 Hz, 1H),2.69-2.53 (m, 2H), 2.16 (dt, J = 12.7, 3.2 Hz, 1H), 1.83 (dt, J = 12.7, 4.2 Hz,1H), 1.76-1.52 (m, 4H), 1.41-1.27 (m, 1H), 1.27-1.14 (m, 1H), 1.14-0.95 (m,10H) ppm. MS (ESI): 705 m / z [M+H] + LC R t Purity (LC-MS method 01): 1.44 min, >99.9% / >99.9% (210 / 254 nm).
[0103] Example 2. Synthesis of Compound 2: N-(5-(3-(3,3-dimethylbutoxy)-5-fluorophenyl)-4-(2,6-dimethylphenyl)thiazol-2-yl)benzenesulfonamide (Compound 2) Step 1. Add benzenesulfonyl chloride (0.192 mL, 1.51 mmol) to a mixture of 5-[3-(3,3-dimethylbutoxy)-5-fluoro-phenyl]-4-(2,6-dimethylphenyl)thiazol-2-yl]benzenesulfonyl chloride (300 mg, 0.75 mmol) (as described in WO2021 / 097057, intermediate C-6a) and pyridine (3.0 mL). Stir the reaction mixture in a microwave oven at 130 °C for 3 h. Cool the reaction mixture to room temperature and dilute with brine (20 mL). Extract the aqueous solution with ethyl acetate (40 mL × 2). Dry the combined organic compounds over anhydrous sodium sulfate, filter, and concentrate. Purify the residue by preparative HPLC to give the title compound N-[5-[3-(3,3-dimethylbutoxy)-5-fluoro-phenyl]-4-(2,6-dimethylphenyl)thiazol-2-yl]benzenesulfonamide (206 mg, 51%) as a white solid.
[0104] LCMS: LC retention time 1.76 min. MS (ESI) m / z 539 [M+H] + .
[0105] 1 H NMR (400 MHz, chloroform-) d ) δ 9.73 (s, 1H), 7.91 (d, J = 7.5 Hz, 2H), 7.52(dt, J = 32.1, 7.3 Hz, 3H), 7.35–7.04 (m, 3H), 6.55–6.21 (m, 3H), 3.66 (t, J =7.2 Hz, 2H), 2.13 (s, 6H), 1.61 (t, J = 7.1 Hz, 2H), 0.95 (s, 9H) ppm.
[0106] Example 3. Synthesis of 4-[[(7S)-1-[2-[(1S)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy]-4-pyridyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-7-yl]oxy]benzoic acid (compound 3) 3 Synthesis Example 3, Method 1 for Synthesizing Compound 3 .
[0107] Step 1. Synthesis of 4-bromo-2-(1-phenylethoxy)pyridine Cesium carbonate (111.08 g, 341 mmol) was added to a solution of 4-bromo-2-fluoropyridine (20 g, 114 mmol) and 1-phenylethanol (13.90 g, 114 mmol) in DMF (200 mL). The mixture was then stirred overnight at 100 °C. The crude product was then purified by rapid chromatography with elution of 10% EtOAc / isohexane to give the title compound (29.0 g, 92% yield) as a yellow solid.
[0108] LC-MS (Method 1): Retention time = 2.45 min. MS (ESI) m / z 174.1 / 176.1 (M-PhCHMe+H) + .
[0109] Step 2.1 Synthesis of tert-butyl 2-(2-(1-phenylethoxy)pyridin-4-yl)hydrazinocarboxylate To a solution of 4-bromo-2-(1-phenylethoxy)pyridine (15.0 g, 53.9 mmol) in 1,4-dioxane (150 mL), tert-butyl N-aminocarbamate (8.55 g, 64.7 mmol), (9,9-dimethyl-9H-oxanthracene-4,5-diyl)bis(diphenylphosphine) (3.12 g, 5.39 mmol), tris(dibenzylacetone)dipalladium (4.94 g, 5.39 mmol), and cesium carbonate (52.71 g, 162 mmol) were added. The mixture was then stirred overnight at 100 °C under argon atmosphere. The crude product was then purified by rapid column chromatography, eluting with 10% EtOAc / isohexane, to give the title compound (16.0 g, 90% yield) as a yellow solid.
[0110] LC-MS (Method 1): Retention time = 2.11 min. MS (ESI) m / z 330 (M+H) + .
[0111] Step 3. Synthesis of 1-(2-hydroxypyridin-4-yl)-3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-indazole-7-one Sulfuric acid (25 mL) was added to a solution of 1-(2-(1-phenylethoxy)pyridin-4-yl)hydrazinocarboxylate tert-butyl ester (10 g, 30.4 mmol) and 2-(benzyloxy)-6-(2,2,2-trifluoroacetyl)cyclohexyl-2-en-1-one in 2,2,2-trifluoroethanol (100 mL). The mixture was then stirred overnight at 80 °C. The mixture was poured into water (500 mL), the pH was adjusted to 8–9 with NaHCO3, and then extracted with EA (3 x 50 mL). The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated. The crude product was then purified by rapid column chromatography, eluting with 10% EtOAc / isohexane, to give the title compound (5 g, 55% yield) as a yellow solid.
[0112] LC-MS (Method 1): Retention time = 1.72 min. MS (ESI) m / z 298.3 (M+H) + Step 4. Synthesis of 1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethyl-1-one 2,2-Difluoro-5-iodo-1,3-benzodioxane (1.40 g, 4.93 mmol) and Pd(PPh3)2Cl2 (138 mg, 0.20 mmol) were added to a solution of 1-ethoxyvinyltri-n-butyltin (1.7 mL, 4.93 mmol) in toluene (20 mL). The mixture was stirred at 90 °C for 12 h under N2, and then cooled to room temperature. HCl (30 mL, 60.0 mmol) was added and the mixture was stirred for 0.5 h. The mixture was extracted with EA (30 mL × 3). The organic layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by rapid column chromatography, eluting with 5% EtOAc / isohexane, to give the title compound (950 mg, 95% yield) as a colorless oil.
[0113] LC-MS (Method 1): Retention time = 2.02 min. MS (ESI) m / z 201.0 (M+H) + .
[0114] 1 H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.3, 1.6 Hz, 1H), 7.69 (d, J = 1.6Hz, 1H), 7.14 (d, J = 8.3 Hz (1H), 2.60 (s, 3H).
[0115] Step 5.1 Synthesis of (2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethanol-1-ol At 0 °C, NaBH4 (340 mg, 8.99 mmol) was added to a solution of 1-(2,2-difluoro-1,3-benzodioxane-5-yl) ethyl ketone (900 mg, 4.50 mmol) in methanol (10 mL), and the mixture was stirred for 2 hours. The mixture was then poured into water (40 mL) and extracted with EA (3 x 30 mL). The organic layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by rapid column chromatography with elution of 10% EtOAc / isohexane to give the title compound as a colorless oil (860 mg, 94.6% yield).
[0116] LC-MS (Method 1): Retention time = 1.94 min. MS (ESI) m / z 185.0 (M-H2O+H) + .
[0117] Step 6. 1-(2-(1-(2,2-difluorobenzo[d][1,3]dioxane-5-yl)ethoxy)pyridine-4- Synthesis of 3-(trifluoromethyl)-1,4,5,6-tetrahydro-7H-indazole-7-one To a solution of 1-(2-hydroxy-4-pyridyl)-3-(trifluoromethyl)-5,6-dihydro-4H-indazole-7-one (4000 mg, 13.5 mmol) in THF (50 mL), 1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethanol (3265 mg, 16.1 mmol) and triphenylphosphine (4236 mg, 16.1 mmol) were added dropwise. After cooling the solution to 0 °C, diethyl azodicarbonate (2.6 mL, 16.1 mmol) was added dropwise at 0 °C, followed by stirring at 25 °C for 1 hour. The solution was concentrated, and the crude product was purified by rapid column chromatography with elution of 10% EtOAc / isohexane to give a racemic product (4500 mg, 69% yield), which was purified by SFC to give two enantiomers of the title compound. The enantiomer eluted first (the larger mobile fraction) was named P1 (2100 mg, 47% yield), and the enantiomer eluted subsequently was named P2 (2000 mg, 44% yield).
[0118] LC-MS (Method 2): Retention time = 2.36 min. MS (ESI) m / z 482.0 (M+H) + .
[0119] Step 7. 1-(2-((S)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethoxy)pyridine Synthesis of pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole-7-ol Sodium borohydride (126 mg, 3.32 mmol) was added to a solution of 1-[2-[(1R)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy]-4-pyridyl]-3-(trifluoromethyl)-5,6-dihydro-4H-indazole-7-one (P2 of step 6 above) (400 mg, 0.831 mmol) in methanol (10 mL). The mixture was then stirred at room temperature for 2 h under argon. The mixture was then quenched with water (50 mL) and extracted with EA (50 mL × 3). The organic layer was washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by rapid chromatography (Biotage, 40 g silica column, 60 mL / min, elution with 0-30% ethyl acetate / petroleum ether for 20 min) to obtain the title compound (350 mg, 82.8%) as a pale yellow oil.
[0120] LCMS (Method 1): Rt 2.38 min. MS (ESI) m / z 300.1 (M+H) + .
[0121] Step 8.4 - ((1-(2-((S)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethoxy) Synthesis of methyl pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-7-yl)oxy)benzoate To a solution of 1-[2-[(1S)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy]-4-pyridyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazole-7-ol (from the product of step 7 above) (800 mg, 1.65 mmol) in THF (10 mL), methyl 4-hydroxybenzoate (302 mg, 1.99 mmol) and PPh3 (521 mg, 1.99 mmol) were added. After stirring the solution at 0 °C for 5 min, DEAD (0.31 mL, 1.99 mmol) was added dropwise at 0 °C. The solution was then stirred at 25 °C for 1 h. The solution was concentrated, and the crude product was then purified by rapid column chromatography with elution of 10% ethyl acetate / isohexane to give a mixture of diastereomers (650 mg, 69% yield), which was further separated by SFC to give the title compound, wherein the first fraction was named P1 (300 mg, 47%; yellow oil) and the second fraction was named P2 (300 mg, 44%; yellow oil).
[0122] LC-MS (Method 1): Retention time = 2.65 min. MS (ESI) m / z 618.2 [M+H] + .
[0123] Step 9.4 - [[(7S)-1-[2-[(1S)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy Synthesis of 4-pyridyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazole-7-yl]oxy]benzoic acid Methyl 4-(((S)-1-(2-((S)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethoxy)pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-7-yl)oxy)benzoate (from product P1 in step 8 above) (300 mg, 0.486 mmol) was added to a solution of methanol (10 mL), THF (10 mL), and water (5 mL). The solution was then stirred overnight at 25 °C. The solution was concentrated under vacuum and purified by preparative HPLC to give the title compound as a white solid (185 mg, 48% yield).
[0124] LC-MS (Method 1): Retention time = 1.86 min. MS (ESI) m / z 602.0 [MH] + .
[0125] 1 H NMR (500 MHz, CH3OH-d4) δ 8.06 (d, J = 7.5 Hz, 1H), 8.03 (d, J = 11 Hz, 2H), 7.16 (dd, J = 7.0, 2.5 Hz, 1H), 7.12 (dd, J = 7.0, 5.0 Hz, 2H), 7.05 (d, J =1.7 Hz, 1H), 7.03 – 6.87 (m, 3H), 6.03 (q, J = 8.0 Hz, 1H), 5.74 (t, J = 4.5 Hz, 1H), 2.87 (d, J = 21 Hz, 1H), 2.63 (ddd, J = 16.7, 11.0, 5.7 Hz, 1H), 2.29 (d, J =17 Hz, 1H), 2.00 (dd, J= 12.2, 6.9 Hz, 1H), 1.95-1.75 (m, 2H), 1.43 (d, J = 8.0Hz, 3H).
[0126] Synthesis Example 3, Method 2 for Synthesizing Compound 3 .
[0127] Synthesis of 4-[[(7S)-1-[2-[(1S)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy]-4-pyridyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-7-yl]oxy]benzoic acid Step 1. Synthesis of 1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethyl-1-one 2,2-Difluoro-5-iodo-1,3-benzodioxane (1.40 g, 4.93 mmol) and Pd(PPh3)2Cl2 (138 mg, 0.20 mmol) were added to a solution of 1-ethoxyvinyltri-n-butyltin (1.7 mL, 4.93 mmol) in toluene (20 mL). The reaction mixture was stirred at 90 °C for 12 h under N2, and then cooled to room temperature. HCl (30 mL, 60.0 mmol) was added and the mixture was stirred for 0.5 h. The mixture was extracted with EA (30 mL × 3). The organic layers were combined, washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by rapid column chromatography, eluting with 5% ethyl acetate / isohexane, to give the title compound (950 mg, 95% yield) as a colorless oil.
[0128] LC-MS (Method 1): Retention time = 2.02 min. MS (ESI) m / z 201.0 (M+H) + .
[0129] 1 H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.3, 1.6 Hz, 1H), 7.69 (d, J = 1.6Hz, 1H), 7.14 (d, J = 8.3 Hz (1H), 2.60 (s, 3H).
[0130] Step 2. Synthesis of (R)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethanol-1-ol At 0℃, towards N2 ( S)-2-methyl-CBSoxazolborane (Reference 1) [(8.25 g, 0.03 mol) in a solution of DCM (200 mL) with added BH3 . Me2S (150 mL, 2 M in DCM). The reaction mixture was stirred at room temperature for 0.5 h, and then a solution of 1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethyl-1-one (60 g, 0.30 mol) in DCM (300 mL) was added dropwise over 1 h at 0 °C. The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was quenched by adding MeOH at 0 °C and then concentrated under vacuum to give a residue, which was purified by rapid silica gel column chromatography (0% to 10% ethyl acetate / petroleum ether) to give the title compound (56 g, 92% yield) as a pale yellow liquid.
[0131] LC-MS: Retention time = 1.75 min. MS (ESI) m / z 185.0 [M-H2O+H] + .
[0132] Step 3. Synthesis of 4-bromo-2-(1-phenylethoxy)pyridine Cs₂CO₃ (111 g, 342 mmol) was added to a solution of 4-bromo-2-fluoropyridine (20.0 g, 114 mmol) and 1-phenylethanol (13.9 g, 114 mmol) in DMF (200 mL). The reaction was stirred overnight at 100 °C. The mixture was poured into water (2 L) and extracted with EA (200 mL × 3). The organic layers were combined, washed with brine, dried over Na₂SO₄, filtered, and concentrated. The crude product was then purified by rapid column chromatography, eluting with 10% ethyl acetate / PE, to give the title compound (29.0 g, 91.8%) as a yellow solid.
[0133] LCMS (Method 1): Retention time = 2.45 min. MS (ESI) m / z 174.1, 176.1 [M-103] + .
[0134] Step 4. Synthesis of tert-butyl 1-(2-(1-phenylethoxy)pyridin-4-yl)hydrazinocarboxylate To a solution of 4-bromo-2-(1-phenylethoxy)pyridine (15.0 g, 53.9 mmol) in 1,4-dioxane (150 mL), tert-butyl N-aminocarbamate (8.6 g, 64.7 mmol), XantPhos (3.1 g, 5.39 mmol), tris(dibenzylacetone)palladium (4.9 g, 5.39 mmol), and Cs₂CO₃ (52.8 g, 162 mmol) were added. The mixture was then stirred overnight at 100 °C under Ar conditions. The mixture was poured into water (2 L) and extracted with EA (200 mL × 3). The organic layers were combined, washed with brine, dried over Na₂SO₄, filtered, and concentrated. The crude product was then purified by rapid column chromatography, eluting with 10% ethyl acetate / PE, to give the title compound (16.0 mg, 90.1%) as a yellow solid.
[0135] LCMS (Method 1): Retention time = 2.11 min. MS (ESI) m / z 226 [M-103] + .
[0136] Step 5. Synthesis of 1-(2-hydroxypyridin-4-yl)-3-(trifluoromethyl)-5,6-dihydro-1H-indazole-7(4H)-one Sulfuric acid (25 mL) was added to a solution of N-amino-N-[2-(1-phenylethoxy)-4-pyridyl]carbamate tert-butyl ester (10.0 g, 30.4 mmol) in 2,2,2-trifluoroethanol (100 mL). The mixture was then stirred overnight at 80 °C. The mixture was poured into water (500 mL) and the pH was adjusted to 8–9 with NaHCO3, followed by extraction with EA (50 mL x 3). The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated. The crude product was then purified by rapid column chromatography, eluting with 10% ethyl acetate / PE, to give the title compound (5.0 g, 55.4%) as a yellow solid.
[0137] LCMS (Method 1): Retention time = 1.72 min. MS (ESI) m / z 298.3 [M+H] + .
[0138] Step 6. (S)-1-(2-(1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethoxy)pyridine Synthesis of pyridin-4-yl)-3-(trifluoromethyl)-5,6-dihydro-1H-indazol-7(4H)-one To a solution of 1-(2-hydroxy-4-pyridyl)-3-(trifluoromethyl)-5,6-dihydro-4H-indazol-7-one (4000 mg, 13.5 mmol) in THF (50 mL), (R)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethanol-1-ol (from the product of step 2 above) (3265 mg, 16.1 mmol) and PPh3 (4236 mg, 16.1 mmol) were added. After cooling the mixture to 0 °C, DEAD (2.6 mL, 16.1 mmol) was added dropwise at 0 °C, followed by stirring at room temperature under N2 for 1 h. The mixture was concentrated, and the crude product was then purified by rapid column chromatography with elution of 10% ethyl acetate / PE to give the crude compound (4.5 g, ee 90%). The crude compound was further purified by SFC to give the title compound (3.2 g, 49%, ee>99%) as a white solid.
[0139] LCMS (Method 2): Retention time = 2.36 min. MS (ESI) m / z 298.0 (M-183) + .
[0140] Step 7. (R)-1-(2-((S)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethoxy) Synthesis of pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole-7-ol In a 200 mL reactor, the product from step 6 (5.0 g, 10.4 mmol) was suspended in IPA (yellow suspension) (10 volumes) at room temperature. TEA (0.6 volumes) and catalyst (R,R)-TsDPEN-RuCl (for cymene) (0.006 wt) were added to the mixture, and three vacuum / nitrogen exchange cycles were applied. Formic acid (0.4 volumes) was slowly added to the mixture over 10 min (exothermic reaction from 20°C to 25°C). The temperature was increased to 45°C, and the solution was stirred for 4 h. The reaction mixture was concentrated under vacuum. Water (10 volumes) was added, and the pH was adjusted to 7–8 with a 5% NaHCO3 aqueous solution, followed by extraction with EA (2 volumes × 3). The organic layers were combined, washed with brine, dried over Na2SO4, filtered, and concentrated. The crude product was purified by rapid column chromatography, eluting with 20% ethyl acetate / isohexane, to give the title compound (3.0 g, 60%) as a yellow solid.
[0141] LCMS (Method 1): Retention time = 1.73 min. MS (ESI) m / z 300 [M-183] + .
[0142] Step 8. 4-(((S)-1-(2-((S)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethyl Synthesis of methyl benzoate (oxy)pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-7-yl)oxy)benzoate To a solution of (R)-1-(2-((S)-1-(2,2-difluorobenzo[d][1,3]dioxacyclopenten-5-yl)ethoxy)pyridin-4-yl)-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole-7-ol (from the product of step 7 above) (3000 mg, 6.2 mmol), methyl 4-hydroxybenzoate (1.1 g, 7.4 mmol) and PPh3 (2.4 g, 9.3 mmol) were added to 10 mL of THF. The mixture was cooled to 0 °C, and DEAD (1.6 g, 9.3 mmol) was added dropwise at 0 °C under N2. The mixture was then stirred at room temperature for 1 h. The mixture was concentrated, and the crude product was then purified by rapid column chromatography, eluting with 10% ethyl acetate / PE, to give the title compound (3.0 g, 79%) as a white solid.
[0143] LCMS (Method 1): Retention time = 2.65 min. MS (ESI) m / z 434.2 [M-183] + .
[0144] Step 9. 4-[[(7S)-1-[2-[(1S)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy Synthesis of 4-pyridyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazole-7-yl]oxy]benzoic acid Methyl 4-[[(7S)-1-[2-[(1S)-1-(2,2-difluoro-1,3-benzodioxane-5-yl)ethoxy]-4-pyridyl]-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazole-7-yl]oxy]benzoate (3.0 g, 4.86 mmol) was added to a solution of methanol (20 mL), THF (20 mL), and water (10 mL). The reaction mixture was stirred overnight at 25 °C. The mixture was then concentrated, and the crude product was purified by preparative HPLC (NH4HCO3) to give the title compound (2204 mg, 75.2%) as a white solid.
[0145] Analysis results (LCMS and 1 The HNMR (H2NMR) was the same as that of the sample obtained by synthesis method 1.
[0146] Example 4. Synthesis of Compound 4. (2R)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12-dioxo-24-oxa-12λ6-thia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionic acid 1-Bromo-2,3,4-trifluoro-5-nitrobenzene Step A: At 0 °C, 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (24 g, 84.7 mmol) was added to a stirred solution of 1,2,3-trifluoro-4-nitrobenzene (30 g, 169.5 mmol) in concentrated sulfuric acid (150 mL). The mixture was stirred overnight at room temperature. The mixture was slowly and carefully added to ice water (600 g ice and 100 mL water) to maintain the temperature below 30 °C, and extracted with heptane (300 mL x 3). The combined organic extracts were washed with water and brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The resulting residue was purified by rapid chromatography (silica gel, heptane) to give the title compound (32 g, 75%) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 8.21 (td, J = 7.2, 2.8 Hz, 1H) ppm.
[0147] 5-(6-bromo-2,3-difluoro-4-nitrophenoxy)-2-fluorobenzyl nitrile Step B: At room temperature, 2-fluoro-5-hydroxybenzyl nitrile (18.9 g, 138.0 mmol) and potassium carbonate (26 g, 1.5 mmol) were added to a stirred solution of 1-bromo-2,3,4-trifluoro-5-nitrobenzene (product of Step A, 32 g, 125.5 mmol) in N,N-dimethylformamide (250 mL). The mixture was stirred for one hour, then diluted with water (300 mL) and extracted with ethyl acetate (250 mL x 3). The combined organic extracts were washed with water and brine, dried over magnesium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (silica gel) to give the title compound (15 g, 30%) as a yellow solid. MS: 373,375 m / z [M+H] + . 1H NMR (400 MHz, CDCl3) δ 8.30 (dd, J = 7.2, 2.4 Hz, 1H), 7.20-7.25(m, 2H), 7.15-7.17 (m, 1H) ppm.
[0148] 5-(4-amino-6-bromo-2,3-difluorophenoxy)-2-fluorobenzyl nitrile Step C: Iron powder (3 g, 53.6 mmol) and ammonium chloride (5.8 g, 107.5 mmol) were added to a stirred solution of 5-(6-bromo-2,3-difluoro-4-nitrophenoxy)-2-fluorobenzyl nitrile (product of step B, 5 g, 13.4 mmol) in ethanol (100 mL) and water (30 mL). The reaction mixture was stirred at 80 °C for four hours, cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (100 mL x 3). The combined organic extracts were washed with water and brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by rapid chromatography (silica gel, heptane / ethyl acetate, v / v, 10 / 1) to give the title compound (3 g, 65%) as a yellow solid. MS: 343, 345 m / z [M+H] + .
[0149] 5-(4-amino-2-bromo-5,6-difluoro-3-iodophenoxy)-2-fluorobenzylnitrile Step D: NIS (4.4 g, 19.6 mmol) was added to 5-(4-amino-6-bromo-2,3-difluorophenoxy)-2-fluorobenzyl nitrile (product of step C, 6.7 g, 19.6 mmol) in a stirred solution of acetic acid (200 mL). The mixture was stirred at room temperature for three hours, diluted with water (200 mL), and extracted with ethyl acetate (150 mL x 3). The combined organic extracts were washed with water and brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by silica gel rapid chromatography (petroleum ether / dichloromethane, v / v, 2 / 1) to give the title compound (8.2 g, 89%) as a yellow solid. 1 H NMR (400 MHz, CDCl3)δ 7.16-7.18 (m, 2H), 7.03-7.04 (m, 1H), 4.56 (s, 2H) ppm. MS: 469, 471 m / z [M+H] + .
[0150] 5-(4-amino-2-bromo-5,6-difluoro-3-((trimethylsilyl)ethynyl)phenoxy)-2-fluorobenzylnitrile Step E: Trimethylsilylacetylene (3.4 g, 34.6 mmol), Pd(Ph3P)2Cl2 (1.2 g, 1.7 mmol), CuI (323 mg, 1.7 mmol), and triethylamine (3.5 g, 34.6 mmol) were added to a stirred solution of 5-(4-amino-2-bromo-5,6-difluoro-3-iodophenoxy)-2-fluorobenzyl nitrile (product of step D, 8.1 g, 17.3 mmol) in N,N-dimethylformamide (200 mL). The reaction mixture was stirred at 30 °C under nitrogen for three hours, diluted with water (300 mL), and extracted with ethyl acetate (250 mL x 3). The combined organic extracts were washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (silica gel, petroleum ether / dichloromethane, v / v, 8 / 1) to give the title compound (5 g, 64%) as a yellow solid. MS: 439, 441 m / z [M+H] + .
[0151] 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorobenzylnitrile Step F: CuI (608 mg, 3.2 mmol) was added to a stirred solution of 5-(4-amino-2-bromo-5,6-difluoro-3-((trimethylsilyl)ethynyl)phenoxy)-2-fluorobenzyl nitrile (product of step E, 700 mg, 1.6 mmol) in N,N-dimethylformamide (7 mL), and the mixture was stirred at 100 °C for four hours in a glove box. The reaction mixture was diluted with water and extracted with ethyl acetate (50 mL x 3). The organic phase was washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography to give the title compound (362 mg, 62%) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ 8.63 (s, 1H), 7.37-7.39 (m, 1H), 7.14-7.23 (m, 2H), 7.04-7.06(m, 1H), 6.67-6.69 (m, 1H) ppm.
[0152] 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorobenzothioamide Step G: 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorobenzyl nitrile (20.00 g, 54.5 mmol) was added to a stirred solution of sodium bisulfite (8.73 g, 109 mmol) and magnesium chloride hexahydrate (11.08 g, 54.5 mmol) in DMF (260 mL). The reaction mixture was stirred at room temperature for 1 hour, then diluted with water (400 mL) and extracted with ethyl acetate (400 mL x 2). The combined organic phases were washed with brine (50 mL), dried over sodium sulfate, filtered, and concentrated to give the title compound (21.00 g, 96%) as a yellow solid. LC-MS: MS (ESI): 401, 403 m / z [M+H] + Retention time: 1.66 minutes; Purity: >99% (254 nm) (LC-MS method 2).
[0153] 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorobenzoimide methyl thiocarbamate hydroiodide Salt Step H: Methyl iodide (5.3 mL, 84.8 mmol) was added to a stirred solution of 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorobenzothioamide (product of step G, 15.50 g, 38.6 mmol) in 120 mL of acetone. The reaction mixture was stirred at 50 °C for 3 hours and concentrated to give the title compound (20.00 g, 95%) as an orange solid. LC-MS: MS (ESI): 415, 417 m / z [M+H] + Retention time: 1.77 minutes; Purity: 75% (254 nm) (LC-MS method 4).
[0154] 7-((tert-butyldimethylsilyl)oxy)-2-(3-iodophenyl)-2,6,6-trimethylheptanoic acid Step B: Add n-butyllithium (2.5M in hexane, 6 mL, 15 mmol) to a solution of diisopropylamide (1.51 g, 15 mmol) in tetrahydrofuran, stirred and cooled (-78 °C). Stir the reaction mixture at this temperature for 30 min, then add hexamethylphosphoramide (2.68 g, 15 mmol) and continue stirring for another 30 min. Over 5 min, add 10 mL of tetrahydrofuran solution of 2-(3-iodophenyl)propionic acid (1.66 g, 6 mmol). Stir the resulting mixture at -78 °C for 30 min. Then add tert-butyl((5-iodo-2,2-dimethylpentyl)oxy)dimethylsilane (intermediate 29C-1, 5.33 g, 15 mmol) in a single addition. Warm the mixture to room temperature and stir for 2 h. After confirmation by LC-MS that the starting material had been consumed, the reactants were quenched with a mixture of 1 M hydrochloric acid (20 mL) and saturated ammonium chloride solution (15 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, and concentrated to give the crude title product (1.99 g, 65%). MS (ESI): 505 m / z [M+H] + .
[0155] 7-Hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptanoic acid Step C: 1 M tetrabutylammonium fluoride (9.6 mL, 9.6 mmol) was added to a solution of tetrahydrofuran (5 mL) containing the product from Step B (4.8 mmol, 2.42 g). The reaction mixture was stirred at 60 °C for 16 hours. After confirmation by LC-MS that the starting material had been consumed, the mixture was acidified with 10 mL of 1 M hydrochloric acid and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with water, dried over sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography to give the title compound (1.03 g, 55%). MS (ESI): 413 m / z [M+Na] + .
[0156] (S)-1-(naphthyl-1-yl)ethyl-1-ammonium(R)-7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptanoate Step D: 7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethyl-heptanoic acid (intermediate 17B, 500.00 g, 1281 mmol) was added to a stirred solution of (S)-(-)-1-(1-naphthyl)ethylamine (127 mL, 705 mmol) in ethyl acetate (7.5 L). The reaction mixture was stirred overnight at room temperature. The solid was collected by filtration, and the filter cake was washed with ethyl acetate (800 mL). The wet solid was then suspended in EtOAc (1.7 L) and stirred at room temperature for 20 min. The mixture was filtered and washed with ethyl acetate (800 mL). The solid was collected and dried in air to give enantiomer 1 (288 g, 40%) of (S)-1-(naphthyl-1-yl)ethyl-1-ammonium 7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethyl-heptanoate. Chiral purity: 95% (90% ee). (Chiral conditions: column: AD-H; mobile phase: n-hexane (0.1% diethylamine): ethanol (0.1% diethylamine) = 95:5; column temperature: 40℃; flow rate: 1.0 mL / min; wavelength: 220 nm; instrument: Shimadzu; the solid salt was desalted with acetonitrile solution of 1N hydrochloric acid before injection).
[0157] The above solution of approximately 90% ee of (S)-1-(naphthyl-1-yl)ethyl-1-ammonium(R)-7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethyl-heptanoate (186 g, 315 mmol) in acetonitrile (7.65 L) was refluxed for 5 hours, then stirred overnight at room temperature. The mixture was filtered and washed with acetonitrile (2 x 450 mL). The solid was collected and dried under vacuum to give the title compound (153 g, 86%). Chiral purity: 99% (98% ee). 1 H NMR (400 MHz, CDCl3) δ 7.84 (t, J = 6.7Hz, 2H), 7.77 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 1.6 Hz, 1H), 7.56 (d, J = 7.1 Hz,1H), 7.52-7.37 (m, 4H), 7.19 (d, J = 8.5 Hz, 1H), 6.92 (t, J = 7.9 Hz, 1H), 4.85(q, J = 6.6 Hz, 1H), 3.19 (dd, J= 42.8, 10.4 Hz, 2H), 1.77-1.66 (m, 1H), 1.61-1.57 (m, 1H), 1.54 (d, J = 6.7 Hz, 3H), 1.38 (s, 3H), 1.28-0.98 (m, 4H), 0.79 (s, 3H), 0.74 (s, 3H) ppm.
[0158] (R)-7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptanoic acid Step E. The chiral salt from step D (233 g, 415 mmol) was suspended in ethyl acetate (1000 mL). The mixture was washed with 1N HCl (5 x 500 mL) and brine, dried over anhydrous sodium sulfate, and concentrated to give the title compound (160.00 g, 99%) as a pale yellow oil. MS (ESI): 413 m / z [M+Na] + Retention time: 1.98 minutes; Purity: 89% (214 nm) (LC-MS method 3).
[0159] (R)-7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptanate benzyl ester Step F: Benzyl bromide (73.6 g, 430 mmol) and potassium carbonate (85.00 g, 615 mmol) were added to a stirred solution of N,N-dimethylformamide (800 mL). The reaction mixture was stirred at room temperature for 16 hours, then diluted with water (1.5 L) and extracted with ethyl acetate (3 x 800 mL). The combined organic phases were washed with brine, dried over sodium sulfate, and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, eluted with 0-25% ethyl acetate / petroleum ether) to give the title compound (190.00 g, 96%) as a pale yellow oil. 1 H NMR (400MHz, CDCl3) δ 7.62 (t, J = 1.7 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.36-7.28 (m,3H), 7.25-7.19 (m, 3H), 7.02 (t, J = 7.9 Hz, 1H), 5.20-5.05 (m, 2H), 3.23 (d, J=4.4 Hz, 2H), 2.04-1.97 (m, 1H), 1.86-1.75 (m, 1H), 1.62 (s, 1H), 1.53 (s,3H), 1.30-1.15 (m, 4H), 0.80-0.77 (m, 6H) ppm. MS (ESI): 503 m / z [M+Na] + Purity: 98% (214 nm); Retention time: 2.14 min (LC-MS method 4). Chiral HPLC: RT = 1.630 min, 99% (98% ee) (Chiral SFC column conditions: column: OJ-3, 4.6 x 100 mm, 3 µm; mobile phase: carbon dioxide / methanol (0.2% 7M ammonia in methanol solution) (90:10); injection volume: 3.00 uL; run time: 6.0 min; flow rate: 3.0 mL / min; back pressure: 2000 psi; column temperature: 40 °C.) (R)-7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)- Benzyl 2,6,6-trimethylheptaate Step G: 7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethyl-2,6,6-trimethyl-2,6,6-tert-butyl heptanoate was exchanged with the product of Step F (190 g, 396 mmol) following the reaction procedure (5 steps) in Example 1 for the preparation of 7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethyl ... m / z [M+Na] + Purity: 97% (214 nm); Retention time: 1.92 min (LC-MS method 3). Chiral HPLC purity: 99.4% (>99% ee, 214 nm), RT = 11.99 min (chiral column conditions: column: OJ-H, 4.6 x 250 mm, 5 µm; mobile phase: hexane (0.1% diethylamine): ethanol (0.1% diethylamine) = 80:20); injection volume: 10.00 uL; run time: 30.0 min; flow rate: 1.0 mL / min; instrument: Shimadzu; wavelength: 214 nm and 254 nm).
[0160] (R)-7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)- 2,6,6-Trimethylheptanoic acid Step H: 10% palladium / carbon (wetted with approximately 55% water, 20 g) was added to a stirred solution of (R)-7-((2-hydroxyethyl)sulfonyl)-2-(3-((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptanate (product of step G, 145 g, 265 mmol) in methanol (1000 mL). The reaction mixture was stirred under hydrogen at 50 °C for 6 hours, cooled to room temperature, and filtered through a diatomaceous earth mat. The filtrate was concentrated to give the title compound (120 g, 99%) as a colorless oil. MS (ESI): 479 m / z [M+Na] + Purity: >99% (214 nm); Retention time: 1.66 min (LC-MS method 3). Chiral HPLC purity: 99.5% (99% ee, 214 nm), RT = 1.61 min (chiral SFC column conditions: column: IG-3, 4.6 x 100 mm, 3 µm; mobile phase: carbon dioxide / methanol (0.2% 7M ammonia in methanol solution) (65:35); injection volume: 5.00 uL; run time: 6.0 min; flow rate: 3.0 mL / min; back pressure: 2000 psi; wavelength: 214 nm; column temperature: 40 °C).
[0161] (R)-3-(3-((R)-7-((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazine)-1-oxo Methyl heptyl-2-phenyl)-2-methylpropionate Step I: 7-hydroxy-2-(3-iodophenyl)-2,6,6-trimethylheptanoate tert-butyl ester was exchanged with the product of Step H (190 g, 396 mmol) following the reaction procedure (2 steps) in Example 1 for the preparation of (2R)-3-(3-(7-(((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazyl)-1-oxohept-2-yl)phenyl)-2-methylpropionate methyl ester to synthesize the title compound (120 g) as a pale yellow oil. MS (ESI): 485 m / z [M+H] + Purity: 92% (214 nm); Retention time: 1.47 min (LC-MS method 3). Chiral HPLC purity: 99.4% (>99% ee, 254 nm), RT = 1.75 min (chiral SFC column conditions: column: AD-3, 4.6 x 100 mm, 3 µm; mobile phase: carbon dioxide / methanol (0.2% 7M ammonia in methanol solution) = 80:20); injection volume: 5.00 uL; run time: 6.0 min; flow rate: 3.0 mL / min; wavelength: 214 nm; column temperature: 40 °C).
[0162] (R)-3-(3-((R)-2-(5-(5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorophenyl)-1- Methyl-1H-1,2,4-triazol-3-yl)-7-((2-hydroxyethyl)sulfonyl)-6,6-dimethylhept-2-yl)phenyl)-2-methyl Methyl propionate Step J: Methyl (R)-3-(3-((R)-7-((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazyl)-1-oxohep-2-yl)phenyl)-2-methylpropionate (product of Step I, 6.60 g, 13.6 mmol) and methyl 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorobenzoimide thiocarbamate hydroiodate (product of Step A, 7.77 g, 14.3 mmol) were added to a stirred solution of pyridine (80 mL). The reaction mixture was stirred overnight at 80 °C. The reaction mixture was quenched with water (400 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic extracts were washed with brine (400 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (120 g silica column, eluted with 0-65% ethyl acetate / petroleum ether) to give the title compound as a solid (7.00 g, 62%). LC-MS: MS (ESI): 833, 835 m / z [M+H] + Retention time: 1.92 minutes; Purity: 97% (214 nm) (LC-MS method 4).
[0163] (R)-3-(3-((R)-2-(5-(5-((4-bromo-6,7-difluoro-1H-indol-5-yl)oxy)-2-fluorophenyl)-1- Methyl-1H-1,2,4-triazol-3-yl)-6,6-dimethyl-7-(vinylsulfonyl)hept-2-yl)phenyl)-2-methylpropionic acid Methyl ester Step K: Triethylamine (3.5 mL, 25.2 mmol) was added to a stirred solution of dichloromethane (80 mL) from the product of step J (7.00 g, 8.40 mmol), followed by the addition of methanesulfonyl chloride (0.72 mL, 9.24 mmol). The mixture was stirred at room temperature for 2.0 h and concentrated. The residue was purified by automated rapid chromatography (120 g silica gel column, eluted with 0-65% ethyl acetate / petroleum ether) to give the title compound (6.20 g, 91%) as a pale yellow solid. LC-MS: MS (ESI): 815, 817 m / z [M+H] + Retention time: 2.01 minutes; Purity: 99% (214 nm) (LC-MS Method 4) (2R)-2-methyl-3-[3-[(6R,13E)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12-dioxane] 24-oxa-12λ6-thia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1 (29),2(30),4,13,15,17,20,22,25,27-decen-6-yl]phenyl]propionate methyl ester Step L: Over 1.5 hours, a solution of the product from step K (5.70 g, 6.99 mmol) in toluene (50 mL) was added dropwise to a solution of triethylamine (9.7 mL, 69.9 mmol) and bis(tri-tert-butylphosphine)palladium (0) (1.07 g, 2.10 mmol) in toluene (600 mL) under stirring and heating (120 °C) (maintained under argon atmosphere). The mixture was stirred at 120 °C for 2 hours and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, eluted with 0-50% ethyl acetate / petroleum ether) to give the title compound (3.50 g, 68%) as a pale yellow solid. LC-MS: MS (ESI): 735 m / z [M+H] + Retention time: 2.06 minutes; Purity: >99% (214 nm) (LC-MS method 3).
[0164] (2R)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12-dioxo- 24-oxa-12λ6-thia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacarbon-1 (29),2(30),4,15,17,20,22,25,27-Nonen-6-yl]phenyl]propionate methyl ester Step M: 10% palladium / carbon (wetted with approximately 55% water, 800 mg) was added to a stirred solution of the product from step L (3.80 g, 5.17 mmol) in 100 mL ethanol. The reaction mixture was stirred under a hydrogen atmosphere at 50 °C for 4 h. The catalyst was removed by filtration, and the solid was washed with ethanol (30 mL x 3). The combined filtrates were concentrated to give the title compound (3.70 g, 97%) as a white solid. LC-MS: MS (ESI): 737 m / z [M+H] + Retention time: 2.04 minutes; Purity: 98% (254 nm) (LC-MS method 3).
[0165] Compound 4: (2R)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12- Dioxo-24-oxa-12λ6-thia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20] 30 C1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionic acid Step N: Lithium hydroxide monohydrate (421 mg, 10.0 mmol) was added to a stirred solution of the product from step M (3.70 g, 5.02 mmol) in tetrahydrofuran (10 mL), methanol (10 mL), and water (10 mL). The reaction mixture was stirred at room temperature for 3 hours, then acidified to pH ~ 6 with 1.0 M hydrochloric acid and extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (120 g silica gel column, eluted with 0-40% acetone / petroleum ether) to give the title compound (3.00 g, 83%) as a white solid. LC-MS: MS (ESI): 723 m / z [M+H] + Retention time: 2.01 minutes; Purity: 98% (254 nm) (LC-MS method 3). 1 H NMR (400 MHz, CD3OD) δ 7.38-7.34 (m, 3H), 7.24-7.22 (m, 1H), 7.14 (t, J =8.0 Hz, 1H), 7.02-6.96 (m, 3H), 6.67 (t, J = 3.2 Hz, 1H), 3.85 (d, J = 2.0 Hz,3H), 3.35-3.30 (m, 2H), 3.29-3.25 (m, 1H), 3.21-3.15 (m, 1H), 2.99-2.88 (m,2H), 2.83-2.79 (m, 1H), 2.63-2.54 (m, 2H), 2.20-2.10 (m, 1H), 1.87-1.77 (m,1H), 1.67 (s, 3H), 1.64-1.55 (m, 1H), 1.39-1.27 (m, 1H), 1.24-1.17 (m, 1H),1.07-0.98 (m, 10H) ppm Example 5. Compound 5. (2S)-3-[3-[(6R)-22,28-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ4-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionic acid diastereomer 2 (S)-3-(3-((R)-7-((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazine)-1-oxo Methyl heptyl-2-phenyl)-2-methylpropionate Step A: In the preparation of 7-((2-((tert-butyldimethylsilyl)oxy)ethyl)sulfonyl)-2-(3-(((R)-3-methoxy-2-methyl-3-oxopropyl)phenyl)-2,6,6-trimethylheptanoate tert-butyl ester (Nekishi coupling step) in Example 1, (R)-3-iodo-2-methylpropionate methyl ester was exchanged for (S)-3-iodo-2-methylpropionate methyl ester, following the reaction procedure sequence described in Example 4 (steps B to I) to prepare the title compound (54 g).
[0166] 2-Fluoro-5-((4-methoxybenzyl)thio)benzylnitrile Step B: Add (4-methoxyphenyl)methanethiol (91 mL, 648 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthracene (1.87 g, 3.24 mmol), Pd2(dba)3 (1.48 g, 1.62 mmol), and diisopropylethylamine (139.57 g, 1080 mmol) to a stirred solution of 4-bromo-1-fluoro-2-isocyanobenzene (108.00 g, 540 mmol) in 1,4-dioxane (750 mL). Stir the reactants overnight at 100 °C under argon atmosphere and concentrate. Dissolve the residue in EtOAc (1000 mL), wash with water and brine, dry over magnesium sulfate, filter, and concentrate. Grind the crude product with methanol (400 mL) to give the title compound (140.00 g, 512 mmol, 95%) as a yellow solid. LC-MS: MS (ESI): 296 m / z [M+Na] + Retention time: 1.97 minutes; Purity: 96% (254 nm) (LC-MS method 4).
[0167] 5-((2-bromo-6-fluoro-3-methyl-4-nitrophenyl)thio)-2-fluorobenzyl nitrile Step C: Anisole (382 mL, 3495 mmol) was added to a stirred solution of the product from Step B (100.22 g, 367 mmol) in trifluoroacetic acid (382 mL, 4956 mmol). The mixture was stirred at 50 °C for 20 h, and then concentrated in the presence of 2.0 g triphenylphosphine. The residue was dissolved in DMF (500 mL) and treated with 3-bromo-1,2-difluoro-4-methyl-5-nitrobenzene (84.00 g, 333 mmol) and potassium carbonate (92.14 g, 667 mmol). The mixture was stirred at room temperature for 1 h, quenched with water (1.5 L), and extracted with ethyl acetate (800 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column x 2, eluted with 0-30% ethyl acetate / petroleum ether) to give the title compound (100.00 g, 260 mmol, 78%) as a pale yellow solid. LC-MS: MS (ESI): not observed, retention time: 2.07 min; purity: 85% (254 nm) (LC-MS method 3). 1 H NMR (400 MHz, DMSO-d6) δ 8.13 (d, J = 8.4 Hz, 1H), 7.97-7.94 (m, 1H), 7.69-7.65 (m, 1H), 7.52 (t, J = 9.2 Hz, 1H), 2.48 (s, 3H) ppm.
[0168] 5-((4-bromo-6-fluoro-1H-indol-5-yl)thio)-2-fluorobenzyl nitrile Step D: 1,1-Di-tert-butoxy-N,N-dimethyl-methylamine (171.03 g, 841 mmol) was added to a stirred solution of the product from Step C (108.00 g, 280 mmol) in DMF (20 mL). The mixture was stirred at room temperature for 2 days, quenched with water (500 mL), and extracted with ethyl acetate (300 mL x 3). The combined organic extracts were washed with brine (2 x 600 mL), dried over sodium sulfate, filtered, and concentrated to give (E)-5-((2-bromo-3-(2-(dimethylamino)vinyl)-6-fluoro-4-nitrophenyl)thio)-2-fluorobenzyl nitrile (110.00 g, 250 mmol, 89%) as a brown oil. LC-MS: MS(ESI): 440, 442 m / z [M+Na] +Retention time: 1.83 minutes; Purity: 29% (214 nm) (LC-MS method 3).
[0169] Iron powder (347.83 g, 6228 mmol) was added to a stirred solution of crude (E)-5-((2-bromo-3-(2-(dimethylamino)vinyl)-6-fluoro-4-nitrophenyl)thio)-2-fluorobenzyl nitrile (228.49 g, 519 mmol) in acetic acid (1.1 L) and toluene (2.6 L). The reaction mixture was stirred at 110 °C for 16 h under argon atmosphere. The mixture was filtered. The filter cake was washed with toluene. The combined filtrates were concentrated. The residue was purified by rapid column chromatography, eluting with 50% dichloromethane / hexane, to give the title compound (115.00 g, 315 mmol, 61%) as a pale yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 11.82 (s, 1H), 7.67 (dd, J = 5.8, 2.5 Hz, 1H), 7.61 – 7.55 (m, 1H),7.48 (d, J = 9.1 Hz, 1H), 7.44 (t, J = 9.1 Hz, 1H), 7.31 (ddd, J = 8.9, 5.0, 2.5Hz, 1H), 6.53 – 6.47 (m, 1H).
[0170] 5-((4-bromo-6-fluoro-1H-indol-5-yl)thio)-2-fluorobenzoimide methyl thiocarbamate hydroiodate Step E: 2-Fluoro-5-((6-Fluoro-4-bromo-1H-indol-5-yl)thio)-2-fluorobenzyl nitrile (product of step D, 35 g, 96 mmol) was exchanged with 5-((4-bromo-6-fluoro-1H-indol-5-yl)oxy)benzyl nitrile, following the reaction procedure sequence described for the synthesis of methyl 5-((4-bromo-6-fluoro-1H-indol-5-yl)oxy)-2-fluorobenzoimide thiocarbamate hydroiodate (two steps) to prepare the title compound (45 g, 83 mmol) as an orange solid. LC-MS: MS (ESI): 413,415 m / z [M+H] + Retention time: 1.04 minutes; Purity: 97% (254 nm) (LC-MS method 5).
[0171] (2S)-2-methyl-3-[3-[(1R)-1-[5-[5-[(4-bromo-6-fluoro-1H-indol-5-yl)thio]-2-fluoro-benzene Methyl propionate of 1-methyl-1,2,4-triazol-3-yl]-6-(2-hydroxyethylsulfonyl)-1,5,5-trimethyl-hexyl]phenyl]propionate Step F: Methyl (S)-3-(3-((R)-7-((2-hydroxyethyl)sulfonyl)-2,6,6-trimethyl-1-(2-methylhydrazyl)-1-oxohept-2-yl)phenyl)-2-methylpropionate (product of step A, 18.00 g, 37.1 mmol) and methyl 5-((4-bromo-6-fluoro-1H-indol-5-yl)thio)-2-fluorobenzoimide thiocarbamate hydroiodate (product of step E, 20.10 g, 37.1 mmol) were added to a stirred solution of pyridine (150 mL). The mixture was stirred at 80 °C for 16 hours, cooled to room temperature, and poured into 400 mL of water. The solution was extracted with ethyl acetate (2 × 200 mL). The combined organic phases were washed with 1 N hydrochloric acid and brine (300 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0-70% ethyl acetate / petroleum ether) to give the title compound (19.00 g, 62%) as a yellow solid. MS (ESI): 831, 833 m / z [M+H] + Retention time: 2.02 minutes; Purity: 87% (214 nm) (LC-MS method 3).
[0172] (2S)-3-[3-[(1R)-1-[5-[5-[(4-bromo-6-fluoro-1H-indol-5-yl)thio]-2-fluoro-phenyl]-1- Methyl methyl-1,2,4-triazol-3-yl]-1,5,5-trimethyl-6-vinylsulfonyl-hexyl]phenyl]-2-methyl-propionate Step G: Triethylamine (9.5 mL, 67.8 mmol) and methanesulfonyl chloride (1.10 equivalent, 1.9 mL, 24.9 mmol) were added to a solution of dichloromethane (150 mL) to the product of step F (18.80 g, 22.6 mmol). The mixture was stirred at room temperature for 2.0 h and concentrated. The residue was purified by automated rapid chromatography (330 silica gel column, eluted with 0-50% ethyl acetate / petroleum ether) to give the title compound (16.00 g, 87%) as a pale yellow solid. MS (ESI): 813, 815 m / z [M+H] + Retention time: 2.13 minutes; Purity: 96% (214 nm) (LC-MS method 3).
[0173] (2S)-3-[3-[(6R,13E)-22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-12λ6,24- Dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacarbon-1(29),2(30),4, 13,15,17,20,22,25,27-decen-6-yl]phenyl]-2-methylpropionate Step H: Under argon atmosphere and at 120 °C, a solution of the product of Step G (15.80 g, 19.4 mmol) in toluene (50 mL) was added dropwise over 2 hours to a stirred solution of triethylamine (27 mL, 194 mmol) and bis(tri-tert-butylphosphine)palladium (0) (1.98 g, 3.88 mmol) in toluene (700 mL). The mixture was stirred at 120 °C for another 0.5 hours and concentrated. The residue was purified by automated rapid chromatography (330 g silica gel column, eluted with 0–50% ethyl acetate / petroleum ether) to give the title compound (9.80 g, 69%) as a yellow solid. MS (ESI): 733 m / z [M+H] + Retention time: 2.10 minutes; Purity: 96% (214 nm) (LC-MS method 3).
[0174] (2S)-3-[3-[(6R)-22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-12λ6,24-disulfide] Hetero-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17, Methyl 20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionate Step I: Add 10% palladium / carbon (wetted with approximately 55% water, 2 g) to a stirred solution of the product from Step H (9.65 g, 13.2 mmol) in 150 mL of ethanol. Stir the reaction mixture under hydrogen at 50 °C for 4 hours, cool to room temperature, and filter through a diatomaceous earth mat. Concentrate the filtrate to give the title compound as a solid (8.90 g, 92%). MS (ESI): 735 m / z [M+H] + Retention time: 2.09 minutes; Purity: 84% (214 nm) (LC-MS method 4).
[0175] (2S)-3-[3-[(6R)-22,28-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-19-(p-tolyl) (sulfonyl)-12λ6,24-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont- 1(29),2(30),4,15,17,20,22,25,27-Nonen-6-yl]phenyl]-2-methylpropionate Step J: 1-(p-Toluenesulfonyl)imidazolium (5.29 g, 23.8 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (3.6 mL, 23.8 mmol) were added to the product of Step I (8.75 g, 11.9 mmol) in a stirred solution of acetonitrile (100 mL). The mixture was stirred overnight at room temperature, diluted with water (200 mL), and extracted with ethyl acetate (2 x 150 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated silica gel column chromatography (120 g silica gel column, eluted with 0-50% ethyl acetate / petroleum ether) to give the title compound (8.30 g, 78%) as a solid. MS (ESI): 889 m / z [M+H] + Retention time: 2.27 minutes; Purity: 90% (214 nm) (LC-MS method 10).
[0176] (2S)-3-[3-[(6R)-22,28-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-19-(p-methyl) (phenylsulfonyl)-12λ6,24λ4-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20] The non-para of triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionate Enantiomer 2 Step K: To the product of Step J (5.00 g, 5.62 mmol), (S,S)-hydrobenzoin (6.02 g, 28.1 mmol), tetraisopropoxide (IV) (4.9 mL, 16.9 mmol), and tert-butyl hydroperoxide (1.52 g, 16.9 mmol) were added to a stirred solution of acetonitrile (100 mL). The mixture was stirred overnight at room temperature, poured into 200 mL of water, and extracted with ethyl acetate (2 x 150 mL). The combined organic phases were washed with brine (300 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (80 g silica gel column, eluted with 0–60% ethyl acetate / petroleum ether) to give the title compound (4.10 g, 81%) as a solid. MS (ESI): 905 m / z [M+H] + Retention time: 2.15 minutes; Purity: 91% (214 nm) (LC-MS method 10).
[0177] (2S)-3-[3-[(6R)-22,28-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ 4-Dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4, The diastereomeric form of methyl 15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionate 2 Step L: Potassium carbonate (0.46 g, 3.31 mmol) was added to the product of step K (1.50 g, 1.66 mmol) in a stirred solution of methanol (20 mL). The mixture was stirred at room temperature for 3 hours, poured into 80 mL of water, and extracted with ethyl acetate (2 x 50 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (40 g silica gel column, eluted with 0-80% ethyl acetate / petroleum ether) to give the title compound as a solid (1.10 g, 88%). MS (ESI): 751 m / z [M+H] + Retention time: 1.99 minutes; Purity: 97% (214 nm) (LC-MS method 10).
[0178] Compound 5: (2S)-3-[3-[(6R)-22,28-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo- 12λ6,24λ4-dithia-3,4,19,30-tetraazapentacyclic[23.3.1.12,5.015,23.016,20]tridecane-1(29), The diastereomeric form of 2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methyl-propionic acid 2 Step M: Lithium hydroxide monohydrate (8.0 mL, 8.00 mmol) (1 M in water) was added to a stirred solution of the product from Step L (1100 mg, 1.46 mmol) in tetrahydrofuran (16 mL). The mixture was stirred at room temperature for 24 hours, then acidified to pH ~ 6 with 1.0 M hydrochloric acid and extracted with ethyl acetate (3 x 40 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (40 g silica gel column, eluted with 0-100% ethyl acetate / petroleum ether) to give a white solid. The white solid was ground with acetonitrile to give the title compound (700 mg, 65%) as a white solid. MS (ESI): 737 m / z [M+H] + Retention time: 2.37 minutes; Purity: 99% (214 nm) (LC-MS method 1). 1 H NMR (400 MHz, CD3OD) δ 8.20-8.10 (m, 1H), 8.00-7.85 (m, 1H), 7.60-7.53 (m, 1H), 7.37 (d, J= 3.2 Hz, 1H), 7.19-6.97 (m, 5H), 6.67 (s, 1H), 3.98-3.80 (m, 4H), 3.71-3.64 (m, 1H), 3.56-3.44 (m, 1H), 3.25-3.00 (m, 3H),2.96-2.88 (m, 1H), 2.64-2.56 (m, 2H), 2.32-2.20 (m, 1H), 2.00-1.90 (m, 1H),1.71 (s, 3H), 1.50-1.35 (m, 3H), 1.21 (s, 3H), 1.14 (s, 3H), 1.07-1.04 (m, 4H) ppm.
[0179] Example 6. Compound 6. (2R)-3-[3-[(6R)-21,22-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ4-dithia-3,4,19,28,30-pentazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionic acid diastereomer 2 4-((6-bromo-2,3-difluoro-4-nitrophenyl)thio)pyridinecarboxylate Step A: At room temperature, thiourea (46.1 g, 606.28 mmol) was added to a stirred solution of 4-chloropyridinecarboxynitrile (80 g, 577.41 mmol) in ethanol (540 mL). The reaction mixture was stirred at 100 °C for 1 hour. After cooling, the resulting salt was filtered off and dried to give solid carbamimidothioate 2-cyanopyridine-4-yl ester hydrochloride (97 g, 78%). LC-MS: MS (ESI): 179 m / z [M+H] + Retention time: 0.35 minutes; Purity: 95% (254 nm) (LC-MS method 6).
[0180] Sodium hydroxide (452 mL, 903.6 mmol) was added to a stirred solution of the above-mentioned thioaminomethyliminocyanopyridine-4-yl ester hydrochloride (REQ-00221-1, 97 g, 451.8 mmol) in DMF (1500 mL) at room temperature. The reaction mixture was stirred at room temperature for 10 min and then treated with 1-bromo-2,3,4-trifluoro-5-nitrobenzene (115.6 g, 451.8 mmol). The mixture was stirred at 60 °C for 1 h, then diluted with ethyl acetate (2 L), washed with water (3 L x 2), dried over magnesium sulfate, filtered, and concentrated. The residue was slurried with petroleum ether (160 mL) and ethyl acetate (400 mL) for 30 min and filtered. The solid was dried under vacuum to give the title compound (61 g, 36%) as a solid. LC-MS: MS(ESI): 372, 374 m / z [M+H] + Retention time: 1.94 minutes; Purity: 99% (254 nm) (LC-MS method 6).
[0181] 4-((4-amino-6-bromo-2,3-difluorophenyl)thio)pyridinecarboxylate Step B: At room temperature, Fe powder (27.5 g, 491.7 mmol) was added to a stirred solution of 4-(6-bromo-2,3-difluoro-4-nitro-phenyl)thiopyridine-2-carboxynitrile (product of Step A, 61 g, 163.9 mmol) in acetic acid (500 mL). The reaction mixture was stirred at 40 °C for 1 hour and concentrated. The residue was diluted with ethyl acetate (1000 mL) and filtered. The filtrate was washed with water (1000 mL x 2), dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (330 g silica gel column, eluted with 0-30% ethyl acetate / petroleum ether) to give the title compound as a solid (48 g, 86%). LC-MS: MS (ESI): 342, 344 m / z [M+H] + Retention time: 1.92 minutes; Purity: 92% (254 nm) (LC-MS method 6).
[0182] 4-((4-amino-2-bromo-5,6-difluoro-3-iodophenyl)thio)pyridinecarboxylate Step C: At room temperature, sulfuric acid (98% in water, 9 mL, 168.3 mmol) and N-iodosuccinimide (31.6 g, 140.2 mmol) were added to a stirred solution of 4-((4-amino-2-bromo-5,6-difluoro-3-iodophenyl)thio)pyridinecarboxynitrile (product of step B, 48 g, 140.2 mmol) in ethanol (480 mL). The reaction mixture was stirred at 40 °C for 1 hour. The mixture was diluted with ethyl acetate (2000 mL), washed with water (2000 mL x 2), dried over magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (330 g silica gel column, eluted with 0-50% ethyl acetate / petroleum ether) to give the title compound (51 g, 78%) as a solid. LC-MS: MS (ESI): 468, 470 m / z [M+H] + Retention time: 1.24 minutes; Purity: 90% (254 nm) (LC-MS method 6).
[0183] 4-((4-amino-2-bromo-5,6-difluoro-3-((trimethylsilyl)ethynyl)phenyl)thio)pyridinecarboxylon Step D: At room temperature, trimethylsilylacetylene (61.1 mL, 435.84 mmol), (Ph3P)2PdCl2 (7.64 g, 10.9 mmol), CuI (4.15 g, 21.8 mmol), and triethylamine (45.6 mL, 326.9 mmol) were added to a stirred solution of 4-((4-amino-2-bromo-5,6-difluoro-3-iodophenyl)thio)pyridinecarboxynitrile (product of step C, 51 g, 108.96 mmol) in DMF (500 mL). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with ethyl acetate (1000 mL), washed with brine (1000 mL × 2), dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0–20% ethyl acetate / petroleum ether) to give the title compound as a solid (34 g, 71%). LC-MS: MS (ESI): 438, 440 m / z [M+H] + Retention time: 2.05 minutes; Purity: 92% (254 nm) (LC-MS method 6).
[0184] 4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridinecarboxylate Step E: At room temperature, CuI (2.95 g, 15.5 mmol) was added to a stirred solution of 4-((4-amino-2-bromo-5,6-difluoro-3-((trimethylsilyl)ethynyl)phenyl)thio)pyridinecarboxylonitrile (product of step D, 34 g, 77.5 mmol) in DMF (300 mL). The reaction mixture was stirred at 100 °C for 2 h, diluted with ethyl acetate (1000 mL), washed with brine (1000 mL × 2), dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0-50% ethyl acetate / petroleum ether) to give the title compound (17 g, 60%) as a solid. LC-MS: MS(ESI): 366, 368 m / z [M+H] + Retention time: 2.02 minutes; Purity: 90% (254 nm) (LC-MS method 6).
[0185] 4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridine-2-thiocarboxamide Step F: At room temperature, 4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridinecarboxynitrile (product of step E, 17 g, 46.4 mmol) was added to a stirred solution of DMF (170 mL) with NaHSxH2O (5.2 g, 92.85 mmol) and MgCl2*6H2O (12.9 g, 46.4 mmol). The reaction mixture was stirred at room temperature for 1 hour, then diluted with ethyl acetate (500 mL), washed with water (500 mL x 2), dried over magnesium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0-60% ethyl acetate / petroleum ether) to give the title compound (17.5 g, 94%) as a solid. LC-MS: MS (ESI): 400, 402 m / z [M+H] + Retention time: 1.57 minutes; Purity: >99% (254 nm) (LC-MS method 6).
[0186] 4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridine-2-thiomethylimine (carbimidothioate) methyl ester Step G: At room temperature, iodomethane (13.6 mL, 218.6 mmol) and sodium bicarbonate (18.4 g, 218.6 mmol) were added to a stirred solution of 4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridine-2-thiocarboxamide (product of step F, 17.5 g, 43.7 mmol) in acetone (200 mL). The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with dichloromethane (500 mL), washed with water (500 mL x 2), dried over magnesium sulfate, filtered, and concentrated to give the title compound as a solid (18 g, 99%). LC-MS: MS (ESI): 414, 416 m / z [M+H] + Retention time: 1.42 minutes; Purity: 86% (254 nm) (LC-MS method 6).
[0187] (R)-3-(3-((R)-2-(5-(4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridin-2-yl)-1- Methyl-1H-1,2,4-triazol-3-yl)-7-((2-hydroxyethyl)sulfonyl)-6,6-dimethylhept-2-yl)phenyl)-2-methyl Methyl propionate Step H: Methyl (2R)-3-[3-[(1R)-6-(2-hydroxyethylsulfonyl)-1,5,5-trimethyl-1-(methylcarbamoyl)hexyl]phenyl]-2-methylpropionate (the product of Step I in Example 4, 12.28 g, 25.3 mmol), 4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridine-2-thiomethyliminocyanide methyl ester (the product of Step G, 10.50 g, 25.3 mmol), pyridine (10 mL, 127 mmol), and magnesium sulfate (30.51 g, 253 mmol) were added to a stirred solution of dichloroethane (100 mL). The reaction mixture was stirred at 80 °C for 5 hours, cooled to room temperature, diluted with 300 mL of water, and extracted with ethyl acetate (300 mL x 3). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated silica gel column chromatography (300 g silica gel column, eluted with 0–70% ethyl acetate / petroleum ether) to give the title compound (10.50 g, 50%) as a yellow solid. LC-MS: MS (ESI): 832, 834 m / z [M+H] + Purity: 95% (214nm), retention time: 1.75 minutes (LC-MS method 10).
[0188] (R)-3-(3-((R)-2-(5-(4-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)pyridin-2-yl)-1- Methyl-1H-1,2,4-triazol-3-yl)-6,6-dimethyl-7-(vinylsulfonyl)hept-2-yl)phenyl)-2-methylpropionic acid Methyl ester Step I: To the product from Step H (10.50 g, 12.6 mmol), methanesulfonyl chloride (1.1 mL, 13.9 mmol) and triethylamine (5.3 mL, 37.8 mmol) were added to a stirred solution of dichloromethane (100 mL). The reaction mixture was stirred at room temperature for 2 hours, diluted with 300 mL of water, and extracted with dichloromethane (3 x 300 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluting with 0–50% ethyl acetate / petroleum ether) to give the title compound (9.50 g, 93%) as a yellow solid. LC-MS: MS (ESI): 814,816 m / z [M+H] + Purity: 98% (214 nm), retention time: 1.98 min (LC-MS method 11).
[0189] (2R)-3-[3-[(6R,13E)-21,22-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-12λ6,24- Dithia-3,4,19,28,30-pentazono-[23.3.1.12,5.015,23.016,20]triacarbon-1(29),2(30), 4,13,15,17,20,22,25,27-decen-6-yl]phenyl]-2-methylpropionate Step J: At 120 °C under argon atmosphere, a solution of the product from Step I (9.50 g, 11.7 mmol) in toluene (50 mL) was added dropwise over 1.5 hours to a stirred solution of bis(tri-tert-butylphosphine)palladium (0) (1192 mg, 2.33 mmol) and triethylamine (16 mL, 117 mmol) in toluene (500 mL). After addition, the reaction mixture was stirred at 120 °C for 1 hour and concentrated. The residue was purified by automated silica gel column chromatography (120 g silica gel column, eluted with 0–50% ethyl acetate / petroleum ether) to give the title compound (4.80 g, 56%) as a pale yellow solid. LC-MS: MS (ESI): 734 m / z [M+H] + Purity: 84% (214 nm), retention time: 2.27 minutes (LC-MS method 11).
[0190] (2R)-3-[3-[(6R)-21,22-difluoro-3,6,10,10-tetramethyl-12,12-dioxo-12λ6,24-disulfide] Hetero-3,4,19,28,30-pentazono-pentacyclic[23.3.1.12,5.015,23.016,20]triacon-1(29),2(30),4,15, Methyl 17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionate Step K: To the product from Step J (4.80 g, 6.54 mmol) in a stirred solution of toluene (100 mL), p-toluenesulfonyl hydrazine (12.18 g, 65.4 mmol) was added. The reaction mixture was stirred at 110 °C for 2 h, cooled to room temperature, diluted with 300 mL of water, and extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluting with 0–50% ethyl acetate / petroleum ether) to give the title compound (3.90 g, 81%) as a white solid. LC-MS: MS (ESI): 736 m / z [M+H] + Purity: 96% (214nm), retention time: 2.10 minutes (LC-MS method 11).
[0191] (2R)-3-[3-[(6R)-21,22-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ 4-Dithia-3,4,19,28,30-pentazapentacyclic[23.3.1.12,5.015,23.016,20]triacont-1(29),2 (30), 4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionate Step L: The product from Step K (3.90 g, 5.30 mmol) was added to a stirred solution of acetonitrile (30 mL) with (1S,2S)-1,2-diphenylethane-1,2-diol (5.68 g, 26.5 mmol), titanium isopropoxide (IV) (4.7 mL, 15.9 mmol), and tert-butyl hydroperoxide (2.2 mL, 15.9 mmol). The reaction mixture was stirred at room temperature for 16 hours, then diluted with 150 mL of water and extracted with ethyl acetate (3 x 150 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluting with 0–50% ethyl acetate / petroleum ether) to give the title compound (3.30 g, 83%) as a yellow solid. LC-MS: MS (ESI): 752 m / z [M+H] + Purity: 79% (214 nm), retention time: 2.03 min (LC-MS method 11).
[0192] (2R)-3-[3-[(6R)-21,22-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ 4-Dithia-3,4,19,28,30-pentazapentacyclic[23.3.1.12,5.015,23.016,20]triacont-1(29),2 (30), diastereomers of methyl nonen-6-yl]phenyl]-2-methylpropionate 2 Step M: A mixture of diastereomers (3.30 g, 4.39 mmol) of the product from Step L was separated by chiral SFC under the following conditions: Instrument: SFC-150 (Waters); Column: IH 20 * 250 mm, 10 µm; Column temperature: 35 °C; Mobile phase: CO2 / methanol [0.2% ammonia (7 M in methanol)] = 60 / 40; Flow rate: 100 g / min; Back pressure: 100 bar; Detection wavelength: 214 nm; Cycle time: 4.58 min; Sample solution: 2700 mg dissolved in 350 ml methanol; Injection volume: 4.5 ml. The major isomer of the title compound (2.10 g, 64%) was obtained as a white solid. LC-MS: MS(ESI): 752 m / z [M+H] + Purity: 99% (214 nm), retention time: 2.14 min (LC-MS method 3).
[0193] (2R)-3-[3-[(6R)-21,22-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ 4-Dithia-3,4,19,28,30-pentazapentacyclic[23.3.1.12,5.015,23.016,20]triacont-1(29),2 (30), diastereomers of 4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methyl-propionic acid 2 Step N: Lithium hydroxide monohydrate (586 mg, 14.0 mmol) was added to a solution of tetrahydrofuran (30 mL) and water (15 mL) from step M (2.10 g, 2.79 mmol). The reaction mixture was stirred at room temperature for 16 hours, then diluted with 100 mL of water, acidified with hydrochloric acid solution to pH ~ 5, and extracted with ethyl acetate (3 x 150 mL). The combined organic extracts were washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was freeze-dried to give (2R)-3-[3-[(6R)-21,22-difluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ4-dithia-3,4,19,28,30-pentazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]-2-methylpropionic acid (1.52 g, 74%) as a white solid. LC-MS: MS (ESI): 738 m / z [M+H] + Purity: >99% (214 nm), retention time: 1.40 min (LC-MS method 5). 1H NMR (400 MHz, CD3OD)δ 8.93-8.10 (m, 2H), 7.45 (s, 1H), 7.12-6.63 (m, 6H), 4.31 (s, 3H), 3.62-3.48(m, 2H), 3.09-2.91 (m, 4H), 2.60-2.45 (m, 3H), 1.74 (s, 4H), 1.53-0.89 (m, 14H) ppm.
[0194] Example 7. Compounds 7A and 7B. Diastereomers 1 and 2 of (2S)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12,24-trioxo-12λ6,24λ4-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionic acid. 5-((6-bromo-2,3-difluoro-4-nitrophenyl)thio)-2-fluorobenzyl nitrile Step A: Trifluoroacetic acid (1000 mL, 12980 mmol) was added to a stirred solution of 2-fluoro-5-((4-methoxybenzyl)thio)benzyl nitrile (the product of Step B in Example 5, 250.00 g, 915 mmol) in anisole (10.0 equivalent, 1000 mL, 9155 mmol). The reaction mixture was stirred at 50 °C for 72 hours and concentrated. The residue was dissolved in 200 mL of DMF. This solution was added dropwise at -60 °C to a suspension of 1-bromo-2,3,4-trifluoro-5-nitrobenzene (212.00 g, 828 mmol) and sodium bicarbonate (138.98 g, 1654 mmol) in DMF (1000 mL). The reaction mixture was stirred at -60 °C for 1 hour under argon, quenched with water (1000 mL), and extracted with ethyl acetate (500 mL x 3). The combined organic extracts were washed with brine (500 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0-40% ethyl acetate / petroleum ether) to give a yellow solid of 5-(6-bromo-2,3-difluoro-4-nitrophenyl)thio-2-fluorobenzyl nitrile (241.00 g, 619 mmol, 75%) containing 17% 5-(4-bromo-2,3-difluoro-6-nitrophenyl)thio-2-fluorobenzyl nitrile. LC-MS: MS (ESI): 389, 391 m / z [M+H] + Purity: >99% (214 nm), retention time: 3.06 minutes (LC-MS method 7).
[0195] 5-((4-amino-6-bromo-2,3-difluorophenyl)thio)-2-fluorobenzyl nitrile Step B: Iron powder (55.97 g, 1002 mmol) was added to a stirred solution of 5-(6-bromo-2,3-difluoro-4-nitro-phenyl)thio-2-fluorobenzyl nitrile (144.00 g, 370 mmol) in acetic acid (600 mL), and the reaction mixture was stirred at 40 °C for 2 hours under argon. The mixture was filtered and concentrated to dryness, and the residue was dissolved in ethyl acetate (1000 mL). The solution was washed with water and brine, dried over magnesium sulfate, filtered, and concentrated. The residue was ground several times with a 10% ethyl acetate solution in hexane. The solid was filtered and dried to give the title compound (105.00 g, 71%) as a yellow solid. LC-MS: MS (ESI): 359, 361 m / z [M+H] + Purity: 90% (214 nm), retention time: 2.76 min (LC-MS method 7).
[0196] 5-((4-amino-2-bromo-5,6-difluoro-3-iodophenyl)thio)-2-fluorobenzylnitrile Step C. At room temperature, N-iodosuccinimide (37.58 g, 167 mmol) was added to 5-((4-amino-6-bromo-2,3-difluorophenyl)thio)-2-fluorobenzyl nitrile (product of step B, 60.00 g, 167 mmol) in a stirred solution of acetic acid (350 mL). The reaction mixture was stirred at room temperature for 3 hours and concentrated. The residue was slurried with ethyl acetate in petroleum ether (10%), then with acetonitrile and dried to give the title compound (65.00 g, 80%). LC-MS: MS (ESI): 485, 487 m / z [M+H] + Purity: 63% (254 nm), retention time: 2.07 min (LC-MS method 8).
[0197] 5-((4-amino-2-bromo-5,6-difluoro-3-((trimethylsilyl)ethynyl)phenyl)thio)-2-fluorobenzylnitrile Step D: Add (trimethylsilyl)acetylene (40.50 g, 412 mmol), cuprous iodide (3.93 g, 20.6 mmol), triethylamine (43 mL, 309 mmol), and bis(triphenylphosphine)palladium(II) chloride (7.24 g, 10.3 mmol) to a stirred solution of 5-((4-amino-2-bromo-5,6-difluoro-3-iodophenyl)thio)-2-fluorobenzyl nitrile (product of step C, 50.00 g, 103 mmol) in DMF (500 mL). Stir the mixture at 30 °C for 3 hours under argon atmosphere. Quench the mixture with water (1000 mL) and extract with ethyl acetate (500 mL × 3). Wash the combined organic extracts with saturated LiCl aqueous solution and brine, dry to Na₂SO₄, filter, and concentrate. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0-20% ethyl acetate / petroleum ether) to give the title compound (39.00 g, 83%) as a yellow solid. LC-MS: MS(ESI): 455, 457 m / z [M+H] + Purity: 84% (254 nm), retention time: 2.40 min (LC-MS method 6).
[0198] 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorobenzyl nitrile Step E: Cuprous iodide (2.76 g, 14.5 mmol) was added to the product of Step D (33.00 g, 72.5 mmol) in a stirred solution of DMF (330 mL). The reaction mixture was stirred at 100 °C for 3 hours under an argon atmosphere, then quenched with water (1000 mL) and extracted with ethyl acetate (50 mL x 2). The combined organic extracts were washed with brine (50 mL x 3), dried over sodium sulfate, filtered, and concentrated. The residue was purified by rapid chromatography (330 g silica gel column, eluted with 0-30% ethyl acetate / petroleum ether) to give the title compound (22.00 g, 57.4 mmol, 79%) as a yellow solid. LC-MS:MS (ESI): 383, 385 m / z [M+H] + Purity: >99% (214 nm), retention time: 2.05 min (LC-MS method 8).
[0199] 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorobenzothioamide Step F: Sodium hydrosulfide (11.69 g, 209 mmol) and 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorobenzyl nitrile (product of step E, 40.00 g, 104 mmol) were added to a stirred solution of magnesium chloride hexahydrate (21.22 g, 104 mmol) in DMF (400 mL). The reaction mixture was stirred at room temperature for 2 hours, quenched with water (400 mL), and extracted with ethyl acetate (400 mL x 2). The combined organic extracts were washed with brine (400 mL x 2), dried over sodium sulfate, filtered, and concentrated to give the title compound (41.00 g, 90%) as a yellow solid. LC-MS: MS (ESI): 417, 419 m / z [M+H] + Purity: 90% (214 nm), retention time: 1.67 min (LC-MS method 9).
[0200] 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorobenzoimide methyl thiocarbamate hydroiodide Step G: Methyl iodide (31 mL, 491 mmol) was added to the product of step F (41.00 g, 98.3 mmol) in acetone (100 mL) under stirring. The reaction mixture was stirred at 50 °C for 2 hours. The mixture was concentrated to give the title compound (56.00 g, 85%) as a yellow solid. LC-MS: MS (ESI): 431, 433 m / z [M+H] + Purity: 83% (214nm), retention time: 1.60 minutes (LC-MS method 9).
[0201] (S)-3-(3-((R)-2-(5-(5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorophenyl)-1- Methyl-1H-1,2,4-triazol-3-yl)-7-((2-hydroxyethyl)sulfonyl)-6,6-dimethylhept-2-yl)phenyl)-2-methyl Methyl propionate Step H: Methyl (2S)-3-[3-[(1R)-6-(2-hydroxyethylsulfonyl)-1,5,5-trimethyl-1-(methylcarbamoyl)hexyl]phenyl]-2-methylpropionate (product of Step A in Example 5, 3.20 g, 8.66 mmol) and methyl 5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorobenzoimide thiocarbamate hydroiodate (product of Step G, 2.80 g, 5.01 mmol) were added to a stirred solution of pyridine (30 mL). The reaction mixture was stirred overnight at 80 °C, quenched with water (50 mL), and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (20 g silica column, eluted with 0-90% ethyl acetate / petroleum ether) to give the title compound as a solid (3.80 g, 68%). LC-MS: MS(ESI): 849, 851 m / z [M+H] + Purity: 98% (214 nm), retention time: 2.01 min (LC-MS method 4).
[0202] (S)-3-(3-((R)-2-(5-(5-((4-bromo-6,7-difluoro-1H-indol-5-yl)thio)-2-fluorophenyl)-1- Methyl-1H-1,2,4-triazol-3-yl)-6,6-dimethyl-7-(vinylsulfonyl)hept-2-yl)phenyl)-2-methylpropionic acid Methyl ester Step I: At room temperature, triethylamine (1.9 mL, 13.4 mmol) and methanesulfonyl chloride (0.45 mL, 5.81 mmol) were added to a stirred solution of dichloromethane (40 mL) from Step H (3.80 g, 4.47 mmol). The reaction mixture was stirred at room temperature for 2 hours and diluted with dichloromethane (40 mL). The mixture was washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (20 g silica gel column, eluted with 0-80% ethyl acetate / petroleum ether) to give the title compound (3.40 g, 91%) as a solid. LC-MS: MS (ESI): 831, 833 m / z [M+H] + Purity: 81% (214 nm). Retention time: 2.11 minutes (LC-MS method 4).
[0203] (2S)-2-methyl-3-[3-[(6R,13E)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12-dioxane] 12λ6,24-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1 (29),2(30),4,13,15,17,20,22,25,27-decen-6-yl]phenyl]propionate methyl ester Step J: At room temperature, a solution of triethylamine (0.96 mL, 6.61 mmol) and bis(tri-tert-butylphosphine)palladium(0) (0.42 g, 0.818 mmol) in toluene (400 mL) was purged with argon for 15 min. At 120 °C, a solution of toluene (20 mL) containing the product from Step I (3.40 g, 4.09 mmol) was added dropwise to this solution over 2 hours. After addition, the mixture was stirred at 100 °C for 2 hours and concentrated. The residue was purified by automated rapid chromatography (20 g silica gel column, eluted with 0-65% ethyl acetate / petroleum ether) to give the title compound (2.40 g, 80%) as a solid. LC-MS: MS (ESI): 751 m / z [M+H] + Purity: 96% (214 nm). Retention time: 2.07 min (LC-MS method 4).
[0204] (2S)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12-dioxo-12 λ6,24-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacarbon-1(29),2 (30), methyl nonen-6-yl]phenyl]propionate Step K: Add 10% palladium / carbon (wetted with approximately 55% water, 1 g) to a stirred solution of the product from Step J (2.40 g, 3.60 mmol) in ethanol (40 mL). Stir the reaction mixture at 50 °C for 2 hours under hydrogen atmosphere. Filter the mixture through a diatomaceous earth pad. Wash the filter cake with ethanol (3 x 50 mL). Concentrate the filtrate. Purify the residue by automated rapid chromatography (20 g silica gel column, eluted with 0-65% ethyl acetate / petroleum ether) to give the title compound as a solid (2.3 g, 85%). LC-MS: MS (ESI): 753 m / z [M+H] + Purity: 98% (214 nm). Retention time: 2.10 min (LC-MS method 4).
[0205] (2S)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12-dioxo- 19-(p-Toluylsulfonyl)-12λ6,24-Dithia-3,4,19,30-Tetraazapentacyclo[23.3.1.12,5.015, 23.016,20]Methyl triacontane-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionate Step L: 1-Toluenesulfonyl-1H-imidazolium (1.78 g, 7.96 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (1.2 mL, 7.96 mmol) were added to a stirred solution of acetonitrile (20 mL) from the product of step K (1.50 g, 1.99 mmol). The reaction mixture was stirred at room temperature for 3 days, quenched with water (20 mL), and extracted with ethyl acetate (2 x 50 mL). The combined organic extracts were washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated rapid chromatography (20 g silica gel column, eluted with 0-80% ethyl acetate / petroleum ether) to give the title compound as a solid (900 mg, 49%). LC-MS: MS (ESI): 906 m / z [M+H] + Purity: >99% (214 nm). Retention time: 2.25 minutes (LC-MS method 4).
[0206] (2S)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12,24-trioxane 19-(p-toluylsulfonyl)-12λ6,24λ4-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015, 23.016,20]Methyl triacontane-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionate Step M: The product from Step L (900 mg, 0.992 mmol) was added to a stirred solution of acetonitrile (20 mL) with (S,S)-hydrobenzoin (1.06 g, 4.96 mmol), tetraisopropoxide (IV) (0.87 mL, 2.98 mmol), and tert-butyl hydroperoxide (0.27 g, 2.98 mmol). The mixture was stirred at room temperature for 4 days, poured into 20 mL of water, and extracted with ethyl acetate (2 x 15 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated silica gel chromatography (20 g silica gel column, eluted with 0-90% ethyl acetate / petroleum ether) to give the title compound (820 mg, 89%) as a yellow solid. LC-MS: MS (ESI): 923 m / z [M+H] + Purity: 89% (214 nm). Retention time: 2.17 minutes (LC-MS method 4).
[0207] (2S)-2-methyl-3-[3-[racemic-(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12, 24-Trioxo-12λ6,24λ4-Dithia-3,4,19,30-Tetraazapentacyclic[23.3.1.12,5.015,23.016,20]tri Methyl decacarbon-1(29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionate Step N: Tetrabutylammonium fluoride (5 mL, 1 M in tetrahydrofuran) was added to a stirred solution of the product from step M (820 mg, 0.888 mmol) in tetrahydrofuran (20 mL). The mixture was stirred overnight at room temperature, poured into 20 mL of water, and extracted with ethyl acetate (2 x 15 mL). The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by automated silica gel chromatography (20 g silica gel column, eluted with 0-90% ethyl acetate / petroleum ether) to give the title compound as a solid (570 mg, 83%). LC-MS: MS (ESI): 769 m / z [M+H] + Purity: 92% (214nm). Retention time: 1.98 minutes (LC-MS method 4).
[0208] (2S)-2-methyl-3-[3-[(6R)-21,22,28-trifluoro-3,6,10,10-tetramethyl-12,12,24-trioxane 12λ6,24λ4-dithia-3,4,19,30-tetraazapentacyclo[23.3.1.12,5.015,23.016,20]triacont-1 (29),2(30),4,15,17,20,22,25,27-nonen-6-yl]phenyl]propionic acid Step O: Lithium hydroxide monohydrate (159 mg, 0.380 mmol) was added to a stirred solution of the product from Step N (570 mg, 0.741 mmol) in tetrahydrofuran (2 mL) and water (2 mL). The reaction mixture was stirred overnight at room temperature, acidified to pH ~ 4 with 1N hydrochloric acid, diluted with ethyl acetate (20 mL), washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by preparative HPLC to give the title compound as a solid (335 mg, 60%, diastereomer 2). LC-MS: MS (ESI): 755 m / z [M+H] + Purity: >99% (214 nm). Retention time: 8.97 minutes (LC-MS method 12). 1 H NMR (500 MHz, CD3OD) δ 8.24-7.82(m, 2H), 7.61 (d, J = 9.0 Hz, 1H), 7.44 (d, J = 3.5 Hz, 1H), 7.13 (t, J = 7.5Hz, 1H), 7.06(s, 1H), 7.04 - 6.94 (m,2H), 6.76 (s, 1H), 4.02-3.87 (m, 1H), 3.85 (d, J = 2.5 Hz, 3H), 3.72-3.61 (m,1H), 3.58-3.44 (m, 1H), 3.25-3.21 (m, 1H), 3.12-2.96 (m, 2H), 2.95-2.87 (m,1H), 2.65-2.53 (m, 2H), 2.31-2.21 (m, 1H), 1.97-1.87 (m, 1H), 1.69 (s, 3H), 1.52-1.34 (m, 3H), 1.19 (s, 3H), 1.11 (s, 3H), 1.06-0.94 (m, 4H) ppm.
[0209] Example 8. Analysis of CFTR maturation by Western blotting Cystic fibrosis submucosal glandular epithelial cells CF submucosal glandular epithelial cells (CFSMEo) - This was derived from the airway of a CF patient (ΔF508 / Q2X) and provided by Dr. Dieter Gruenert, University of California-San Francisco. (CFSMEo)- Cells were cultured at 37°C and 5% CO2 in minimum essential medium (MEM) containing Earle's salt and non-essential amino acids, supplemented with 10% (v / v) fetal bovine serum, 2 mM L-glutamine, and 1x (v / v) penicillin / streptomycin, and grown in tissue culture-treated flasks coated with an extracellular matrix (ECM) mixture consisting of 10 µg / mL human fibronectin, 30 µg / mL bovine collagen type I, and 100 µg / mL bovine serum albumin in LHC basal medium.
[0210] CFTR mammalian expression construct Using standard techniques, CFTR and ΔF508-CFTR were each cloned into pcDNA3.0, thereby providing a cytomegalovirus promoter and an early polyadenylation signal for SV40 expression in mammalian cells (Sambrook et al., 1989).
[0211] nuclear transfection Following the manufacturer's instructions, using the Lonza 4D-Nucleofector core unit (Lonza, catalog number AAF-1002B) and X unit (Lonza, catalog number AAF-1002X) and SF cell line 4D-Nucleofector X kit L (Lonza, catalog number V4XC-2024), transiently transfected CFSMEo cells with the CFTR expression construct. - Cells. In short, cells were treated with a concentration of 5.0 × 10⁻⁶. 7 Nuclear transfection with 4 µg plasmid deoxyribonucleic acid (DNA) per cell / mL, and at a concentration of 2.4 × 10⁻⁶ cells / mL. 5 Cells / well were plated on collagen-coated 6-well plates (Corning Inc., Corning, NY).
[0212] Western blot assay CFSMEo cells transiently transfected with wild-type CFTR or ΔF508-CFTR - Cells at 3.2 × 10 5Cells / well were plated in collagen-coated 6-well plates (Corning Inc.). Twenty-four hours post-transfection, CFTR modulators were applied and incubation was allowed for 48 hours. Cell lysates were then harvested in cold IP lysis buffer (Pierce, Rockford, IL) supplemented with an EDTA-free protease inhibitor (Pierce). After quantification using a diquinoline carboxylate assay (Pierce), 5 µg of each sample was separated on a Novex 4% to 12% Tris-glycine Plus gel (Invitrogen, Waltham, MA) and transferred to nitrocellulose membranes using the iBlot 2 dry blot system (Invitrogen). The blots were then incubated with UNC-596 human CFTR-specific monoclonal antibodies (lot numbers 596TJ100285 and 210628TJ20220317) supplied by the Cystic Fibrosis Foundation, University of North Carolina-Chapel Hill. To control loading, the second imprint is compared with mouse Na. + / K + Incubate together with the ATPase monoclonal antibody (Millipore, catalog number 050369). Normalize each sample to the loaded Na... + / K + After ATPase control, the maturation level of CFTR was quantified using ImageJ software (National Institute of Health, Bethesda, MD) via density assay.
[0213] Example 9. Analysis of CFTR channel function Research Design CFhBE cells or CFTR wild-type hBE cells were expanded and seeded onto semipermeable membranes and cultured at the air-liquid interface for 15 to 20 days to allow for tight junction formation and apical CFTR expression. At this point, CFhBE cells were treated with the specified modulator using a Tecan D300 digital dispenser and incubated at 37°C in a humidified chamber for 48 hours. After 48 hours, the cells were loaded horizontally onto a TECC24 platform (EP Design, Bertem, Belgium), and the plate was filled with symmetrical physiological saline containing glucose (“PS+”, in mM: 150 NaCl, 5 KCl, 2 CaCl, 1 MgCl, 10 HEPES, 10 glucose, pH 7.4 (using HCl)). Transepithelial voltage and resistance were recorded in current-clamp mode, and the equivalent current (Ieq) was calculated according to Ohm's law (V = IR, where V is the voltage across the conductor, I is the current flowing through the conductor, and R is the resistance provided by the conductor to the current flow). After obtaining baseline current readings, 10 µM benzamil was added to inhibit epithelial sodium channels, thus eliminating all non-CFTR conductance. Once a stable baseline was reached, foscolline (10 µM) was then added to stimulate CFTR-dependent chloride ion conduction; finally, 20 µM bumetanide was added to inhibit chloride ion transport.
[0214] Data Analysis Bar graphs were plotted by subtracting the baseline minimum current after benzamir addition, and the area under the curve (AUC) for each well between foscohrin and bumetanide addition was calculated. Values were expressed as multiples relative to tezacotto / ivacalto / elecarto (used as an in-plate control) alone, or as a percentage of wild-type CFTR current. AUC served as an indicator of CFTR activity and the recovery of epithelial chloride secretion function in response to different therapeutic agents. Bar graphs are shown as mean ± standard error (SE).
[0215] Example 10. Analysis of CFTR maturation by Western blotting The effect of the test reagent or combination thereof on CFTR-mediated transepithelial chloride ion transport was measured using TECC24 recording analysis. The test reagent was dissolved in DMSO. The dissolved test reagent was then mixed with an incubation medium containing DMEM / F12, Ultroser G (2%; Crescent Chemical, catalog 67042), Hyclone Fetal Clone II (2%; GE Healthcare, catalog SH30066.02), bovine brain extract (0.25%; Lonza, catalog CC-4098), insulin (2.5 μg / mL), IL-13 (10 ng / mL), hydrocortisone (20 nM), transferrin (2.5 μg / mL), triiodothyronine (500 nM), ethanolamine (250 nM), adrenaline (1.5 μM), phosphoethanolamine (250 nM), and retinoic acid (10 nM). Primary human bronchial epithelial cells (CF-HBE cells; from the University of North Carolina Cystic Fibrosis Tissue Procurement Center) from ΔF508 homozygous CF donors were grown on Transwell HTS 24-well cell culture inserts (Costar, catalog number 3378) and exposed to test reagents or controls dissolved in incubation medium. CF-HBE cells were cultured at 36.5°C for 48 hours and then TECC24 recordings were performed with or without one or more test reagents (at a final concentration of 1 μmol or as indicated), a positive control, or a mediator (DMSO).
[0216] Following incubation, transwell cell culture inserts containing the assay reagent or a combination thereof, or control treatments, were loaded onto a TECC24 device (TECC v7 or MTECC v2; EP Design). Four AgCl electrodes per well, configured in current-clamp mode, were used to record transepithelial voltage (VT) and resistance (TEER). Both the apical and basal outer baths contained (mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 Hepes, and 10 glucose (adjusted to pH 7.4 with NaOH). To inhibit basal Na+ uptake, the ENaC inhibitor benzamir (10 μM) was added to the bath. Then, the adenylate cyclase activator fostochne (10 μM) was added to the bath to activate CFTR. At the end of the experiment, specificity was confirmed by adding the CFTR inhibitor-172 (20 μM) to the bath to prevent fostochne-stimulated Cl- transport. VT and TEER records were digitally acquired at regular intervals using TECC or MTECC software (EP Design). VT and TEER were converted into equivalent transepithelial Cl- currents (IEQ), and the area under the curve (AUC) of the IEQ time course between the addition of foscocorine and the CFTR inhibitor-172 was generated using Excel (Microsoft). Efficacy was expressed as the ratio of the test agent AUC to the mediator AUC. EC50 was generated based on AUC using a nonlinear regression log(agonist) versus response function in Prism software (Graphpad) with HillSlope = 1 fixed.
[0217] If an assay agent increases the AUC of fosco-coated IEQ in CF-HBE cells relative to the mediator, and this increase is inhibited by the CFTR inhibitor-172, then the assay agent is considered a CFTR corrector. Data are shown in Table 2 below.
Claims
1. A method for treating a CFTR-mediated disease or condition in a subject of need, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and an ICL4 corrector.
2. The method of claim 1, wherein the NBD1 stabilizer and the ICL4 corrector are applied simultaneously.
3. The method of claim 1, wherein the NBD1 stabilizer is applied before the ICL4 corrector.
4. The method of claim 1, wherein the NBD1 stabilizer is applied after the ICL4 corrector.
5. A method for treating a CFTR-mediated disease or condition in a subject in need, comprising administering a therapeutically effective amount of an NBD1 stabilizer to the subject, wherein the subject has previously received treatment with an ICL4 corrector.
6. A method of treating a CFTR-mediated disease or condition in a subject in need, comprising administering a therapeutically effective amount of an ICL4 corrector to the subject, wherein the subject has previously received treatment with an NBD1 stabilizer.
7. The method of any one of claims 1 to 6, further comprising administering a TMD1 corrector to the subject.
8. A method of treating a subject with a CFTR-mediated disease or condition, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and a TMD1 corrector.
9. The method of claim 1, wherein the NBD1 stabilizer and the TMD1 corrector are applied simultaneously.
10. The method of claim 1, wherein the NBD1 stabilizer is applied before the TMD1 corrector.
11. The method of claim 1, wherein the NBD1 stabilizer is applied after the TMD1 corrector.
12. A method of treating a CFTR-mediated disease or condition in a subject in need, comprising administering to the subject a therapeutically effective amount of an NBD1 stabilizer, wherein the subject has previously received treatment with a TMD1 corrector.
13. A method of treating a CFTR-mediated disease or condition in a subject in need, comprising administering a therapeutically effective amount of a TMD1 corrector to the subject, wherein the subject has previously received treatment with an NBD1 stabilizer.
14. The method of any one of claims 8 to 13, further comprising administering an ICL4 corrector to the subject.
15. A method of treating a subject with a CFTR-mediated disease or condition, comprising administering to the subject a therapeutically effective amount of a combination of an NBD1 stabilizer and a CFTR enhancer.
16. The method of claim 1, wherein the NBD1 stabilizer and the CFTR synergist are administered simultaneously.
17. The method of claim 1, wherein the NBD1 stabilizer is administered before the CFTR synergist.
18. The method of claim 1, wherein the NBD1 stabilizer is administered after the CFTR synergist.
19. A method of treating a CFTR-mediated disease or condition in a subject in need, comprising administering to the subject a therapeutically effective amount of an NBD1 stabilizer, wherein the subject has previously received treatment with a CFTR enhancer.
20. A method of treating a CFTR-mediated disease or condition in a subject in need, comprising administering to the subject a therapeutically effective amount of a CFTR enhancer, wherein the subject has previously received treatment with an NBD1 stabilizer.
21. The method of any one of claims 15 to 20, further comprising administering a TMD1 corrector to the subject.
22. The method of any one of claims 15 to 21, further comprising administering an ICL4 corrector to the subject.
23. The method of any one of claims 1 to 22, wherein the NBD1 stabilizer is a compound selected from the group consisting of: 、 、 、 and , Or its pharmaceutically acceptable salt.
24. The method of any one of claims 1 to 23, wherein the ICL4 corrector is a compound selected from the group consisting of: and Or its pharmaceutically acceptable salt.
25. The method of any one of claims 1 to 23, wherein the TMD1 corrector is a compound selected from the group consisting of: and , Or its pharmaceutically acceptable salt.
26. The method of any one of claims 1 to 25, wherein the CFTR synergist is a compound selected from the group consisting of: and Or its pharmaceutically acceptable salt.
27. The method of any one of claims 1 to 26, wherein the CFTR-mediated disease or condition is selected from the group consisting of: cystic fibrosis, asthma, smoking-induced COPD, chronic bronchitis, sinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility due to congenital bilateral vas deferens agenesis (CBAVD), mild lung disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation disorders. - Fibrinolysis defects, protein C deficiency, type 1 hereditary angioedema, lipid metabolism defects, familial hypercholesterolemia, type 1 chylomicronemia, abeta-lipoproteinemia, lysosomal storage diseases, I-cell disease / pseudo-Heller's disease, mucopolysaccharidosis, Sandhof / Tai-Sachs disease, Krieger-Najjar disease type II, polyendocrine disorders / hyperinsulinemia, diabetes mellitus, Laren dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, and carbohydrate metabolism disorders (CDG). Type 1, congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, diabetes insipidus (DI), neurohypophysiological DI, renal DI, Charcot-Marie-Tus syndrome, Perizaus-Metzbach disease, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, various polyglutamine neurological disorders, Huntington's disease, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, globus pallidus-Lewy body disease, myotonic dystrophy, spongiform dystrophy Encephalopathy, hereditary Creutzfeldt-Jakob disease, Fabry disease, Straussler-Scharinkel syndrome, COPD, dry eye syndrome, Sjögren's syndrome, osteoporosis, osteopenia, bone healing and bone growth, bone repair, bone regeneration, reduced bone resorption, increased bone deposition, Gohan syndrome, chloride channelopathies, congenital myotonia, Barth syndrome type III, Dent disease, hypertonia, epilepsy, hypertonia, lysosomal storage disease, Angelman syndrome, primary ciliary dyskinesia (PCD), PCD with visceral inversion, PCD without visceral inversion, and ciliary dysplasia.
28. The method of claim 27, wherein the CFTR-mediated disease or condition is selected from the group consisting of diseases or conditions selected from cystic fibrosis, congenital bilateral vas deferens agenesis (CBAVD), acute, relapsing or chronic pancreatitis, disseminated bronchiectasis, asthma, allergic pulmonary aspergillosis, chronic obstructive pulmonary disease (COPD), chronic sinusitis, dry eye syndrome, protein C deficiency, abeta-lipoproteinemia, lysosomal storage disease, type 1 chylomicronemia, mild lung disease, lipid metabolism defects, type 1 hereditary angioedema, coagulation-fibrinolysis, hereditary hemochromatosis, CFTR-associated metabolic syndrome, chronic bronchitis, constipation, pancreatic insufficiency, hereditary emphysema, and Sjögren's syndrome.
29. The method of any one of claims 1 to 28, wherein the CFTR-mediated disease or condition is cystic fibrosis.
30. The method of any one of claims 1 to 29, wherein the subject is a human.
Citation Information
Patent Citations
Substituted chromanes and method of use
WO2016069757A1
Substituted tricyclics and method of use
WO2017009804A1
Heteroaryl substituted pyridines and methods of use
WO2017208115A1
5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient CFTR activity
WO2021097057A1
Indole compounds and methods of use
WO2023034992A1
